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Gräff J, Kim D, Dobbin MM, Tsai L-H. Epigenetic Regulation of Gene Expression in Physiological and Patho-
logical Brain Processes. Physiol Rev 91: 603–649, 2011; doi:10.1152/physrev.00012.2010.—Over the past decade, it
has become increasingly obvious that epigenetic mechanisms are an integral part of a multitude of brain functions
that range from the development of the nervous system over basic neuronal functions to higher order cognitive
processes. At the same time, a substantial body of evidence has surfaced indicating that several neurodevelopmental,
neurodegenerative, and neuropsychiatric disorders are in part caused by aberrant epigenetic modifications. Because
of their inherent plasticity, such pathological epigenetic modifications are readily amenable to pharmacological
interventions and have thus raised justified hopes that the epigenetic machinery provides a powerful new platform
for therapeutic approaches against these diseases. In this review, we give a detailed overview of the implication of
epigenetic mechanisms in both physiological and pathological brain processes and summarize the state-of-the-art of
“epigenetic medicine” where applicable. Despite, or because of, these new and exciting findings, it is becoming
apparent that the epigenetic machinery in the brain is highly complex and intertwined, which underscores the need
for more refined studies to disentangle brain-region and cell-type specific epigenetic codes in a given environmental
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condition. Clearly, the brain contains an epigenetic “hotspot” with a unique potential to not only better understand
its most complex functions, but also to treat its most vicious diseases.
I. INTRODUCTION
During the first decade after the completion of the
Human Genome Project, much of molecular biology’s
focus has been shifted from the raw sequence of genes to
their regulation over time and in response to intra- and
extracellular stimuli. Much like a book on a shelf, genes
do not exert effects by their mere presence; rather, the
pages of the book, i.e., the chromatin, need to be opened
first so that the words, i.e., the genes, can be read and
interpreted accordingly. The “epigenetic” regulation of
gene expression precisely refers to this process. The term
epigenetics derives from the greek prefix epi, which lit-
erally means “on” or “above,” and thus defines what is
occurring on the physical support of the genes, the chro-
matin.
The developmental biologist Conrad Hal Waddington
(1905–1975) coined the term epigenetics in 1940, and
defined it as “ . . . the interactions of genes with their
environment which bring the phenotype into being” (351).
By this explanation, he had already described the first of
two important characteristics of epigenetic processes,
which is their plasticity. In 1942, Waddington extended his
original definition stating “ . . . it is possible that an adap-
tive response can be fixed without waiting for the occur-
rence of a mutation . . . ” (350), and thereby framed the
second important aspect of epigenetic processes, which is
their potential heritability and, thus, long-term stability.
Owing to this Janus-faced property, epigenetic mecha-
nisms provide an organism with the molecular means to
promptly react to environmental contingencies with sta-
ble alterations in gene expression.
The brain is arguably one of the most complex tis-
sues, in part because it enables its bearer to readily sense,
and enduringly remember, its environment. With our cur-
rent knowledge of neuroscience, it therefore seems obvi-
ous that epigenetic mechanisms must operate during the
development of the central nervous system (CNS), in
synaptic plasticity and during learning and memory. How-
ever, when Francis Crick (1916–2004) in 1984 proposed
that “memory might be coded in alterations to particular
stretches of chromosomal DNA” (67), the echo in the
scientific community was rather modest (Fig. 1). It took
another 20 years until histone acetylation, a common
form of epigenetic modification, was for the first time
shown to be dynamically altered during memory forma-
tion (187). Since then, however, the number of studies
addressing epigenetic mechanisms in the CNS has
FIG. 1. Development of the number of citations including the term epigenetic. Shown is the number of citations per year that include the term
epigenetic in all research fields combined, and in the field of neurosciences. Citation numbers were retrieved from PubMed
(http://www.ncbi.nlm.nih.gov/sites/entrez).
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steadily increased (Fig. 1), and with them the awareness
that, not only do epigenetic mechanisms play pivotal roles
in normal CNS functions, but their dysregulation also
underlies a variety of CNS diseases. In this review, we
give a detailed account of the implication of epigenetic
mechanisms in physiological CNS functions, and outline
the current knowledge of aberrant epigenetic programs in
neurodevelopmental, psychiatric, and neurodegenerative
disorders. Because aberrant epigenetic programs are po-
tentially reversible, we also review the state-of-the-art of
approaches to counteract epigenetic dysfunction in CNS
disorders. Finally, we discuss where the study of epige-
netics in the CNS might lead in the future.
II. TERMINOLOGY
Epigenetics is most commonly defined as “the study
of mitotically and/or meiotically heritable changes in gene
function that cannot be explained by changes in DNA
sequence” (295). This definition, however, is not particu-
larly well suited for the nervous system in which there is
an overall absence of mitosis. We therefore propose a
more recent definition of epigenetics for the purpose of
this review, which reads epigenetics as “the structural
adaptation of chromosomal regions so as to register, sig-
nal, or perpetuate altered activity states” (27). In this
definition, the three major levels of epigenetic changes
are embodied (Fig. 2): 1) chemical modifications at the
level of the nucleotides, which include DNA methylation
and RNA interference (RNAi); 2) modifications at the
level of histones that encompass posttranslational modi-
fications (PTMs) of histone proteins and the incorpora-
tion of histone variants; and 3) nucleosome remodeling,
which refers to ATP-dependent processes that regulate
the accessibility of nucleosomal DNA. We first give a brief
overview of each of these modifications, and then de-
scribe their implications for CNS function in more detail
in the relevant sections.
A. Epigenetic Modifications of the DNA
1. DNA methylation
DNA methylation refers to the covalent addition of a
methyl group from the methyl donor S-adenosylmethio-
nine (SAM) to a cytosine base within the DNA. This
reaction is catalyzed by a family of DNA methyltrans-
ferases (DNMTs), with DNMT1 being the main enzyme in
mammals (177). DNA methylation most often occurs on
CpG dinucleotides, but several instances of non-CpG
methylation have also been found in mammals (279).
Most CpG dinucleotide methylation occurs outside of
CpG-rich clusters, called CpG islands. DNA demethyl-
ation can be passive, when it is simply the absence of
methylation maintenance, or active, via the actions of
recently discovered enzymes such as DNA glycolases
(372).
Traditionally, DNA methylation in the promoter re-
gion of a gene has been associated with decreased tran-
scriptional activity (289). This is because DNA methyl-
ation can inhibit the binding or transcription factors di-
rectly by “masking the DNA” or indirectly, by recruiting
methyl-CpG binding proteins (MBPs), which possess re-
pressive chromatin-remodeling activities (26, 167). How-
FIG. 2. Overview of possible epigenetic
modifications. Inherent to all types of epige-
netic modifications is the regulation of the
accessibility of the chromatin structure to
the transcription machinery. See text for
more details. [Modified from Gräff and Man-
suy (113), with permission from Elsevier.]
PHYSIOLOGICAL AND PATHOLOGICAL EPIGENETICS IN THE BRAIN 605
Physiol Rev • VOL 91 • APRIL 2011 • www.prv.org
ever, as highly methylated stretches of DNA have also
been found in the promoter and coding regions of actively
transcribed genes, the functional impact of DNA methyl-
ation on transcriptional activity is not that clear-cut (325,
362).
DNA methylation is abundant on permanently si-
lenced imprinted genes, and thus has often been viewed
as a stable epigenetic modification. However, it is now
clear that DNA methylation is a highly dynamic process
that is fully reversible, making the aberrant DNA methyl-
ation patterns found in some cancers and in various dis-
orders of the nervous system potentially amenable to
pharmacological treatments.
2. RNAi
Epigenetic alterations of the DNA can also be pro-
duced by double-stranded RNA (dsRNA) and protein
components of the RNAi machinery. Here, it is thought
that small RNAs produced by cleavage of dsRNA serve as
sequence-specific facilitators to guide other enzymes of
the epigenetic machinery into place (222). Thus, when
members of the RNAi machinery such as the genes piwi
and homeless in Drosophila melanogaster are mutated,
centromeric heterochromatin formation is inhibited. Like-
wise, in the fission yeast Schizosaccharomyces pombe,
deletions of genes involved in the RNAi machinery, such
as argonaute, result in reduced heterochromatin forma-
tion, which is accompanied by reduced histone methyl-
ation on lysine (K) 9 on histone (H) 3, a marker of tran-
scriptional repression (181). In mammals, additionally,
short-interfering RNAs (siRNAs) were shown to induce
DNA methylation alongside H3 methylation, resulting in
decreased levels of gene expression (222). Noncoding
RNAs, therefore, have a conserved epigenetic role in gene
repression both at the transcriptional and posttranscrip-
tional level.
B. Epigenetic Modifications of Histones
1. Posttranslational histone modifications
Histones are basic proteins that regulate the compac-
tion of the chromatin. Histones consist of a globular
histone core and a loosely structured NH2-terminal his-
tone tail, which protrudes out of the tight histone-DNA
assembly termed the nucleosome. A nucleosome consists
of an octamer of the four core histones H2A, H2B, H3, and
H4 in duplicates, around which 147 base pairs of DNA are
wrapped to form the 10-nm-thick primary structure of the
chromatin (Fig. 3A). Nucleosomes are linked together by
the linker histone H1, which is not part of the nucleosome
per se. PTMs can occur on all histones, and although the
shorter COOH-terminal tail of the core histones can also
undergo modification, the majority of histone PTMs oc-
curs on the NH2-terminal tail and consists of acetylation,
methylation, phosphorylation, ubiquitination, and sumoy-
lation. Due to their chemical properties, these epigenetic
modifications are capable of altering the condensation of
the chromatin and, as a consequence, the accessibility of
the DNA to the transcriptional machinery.
A) ACETYLATION. Histones can become acetylated on
lysine (K) residues (Fig. 3B). Histone acetylation has been
linked to transcriptional activation, since the acetyl group
addition neutralizes the positive charge of the -amino
group of the lysine, leading to decreased affinity between
the histone tail and the negatively charged DNA (37). The
enzymes regulating histone acetylation consist of the hi-
stone acetyltransferases (HATs) and histone deacetylases
(HDACs), the latter of which is divided into two func-
tional categories. Eleven zinc-dependent HDACs com-
prise the class I, IIa, IIb, and IV HDACs, in addition to the
seven members of the class III NAD-dependent HDACs,
the sirtuins (156). It is interesting to note that some
acetylateable residues are functionally more consequen-
tial than others. For instance, in the yeast Saccharomyces
cerevisiae, H4K16 affects its own subset of genes,
whereas other genes are overlappingly regulated by all of
H4K12, K8, and K5 acetylation marks, but not by K16 (75).
B) METHYLATION. Histone methylation occurs on both
lysine and arginine (R) residues (Fig. 3B). This epigenetic
modification is a double-edged sword in terms of its effect
on transcriptional activity, as it has been shown to asso-
ciate with both transcribed and silenced genes (168, 271).
Moreover, arginine residues can be both mono- and dim-
ethylated, and lysine residues can be mono-, di-, and
trimethylated. These degrees of histone methylation can
have differing roles on the regulation of gene expression
(312), most likely because effector proteins, such as tran-
scriptional coactivators, recognize mono-, di-, and trim-
ethylated epitopes with different affinities (168). For ex-
ample, monomethylated H3K4 has been found on both
expressed and repressed genes, whereas trimethylated
H3K4 is exclusively associated with silenced genes (192).
Finally, the exact location of the methylation within a
given genetic region is crucial for determining its effect on
gene transcription. H3K9 methylation within the coding
region of a gene has been found to correlate with the gene
being expressed, whereas the same modification is asso-
ciated with inactive transcription when found in the pro-
moter region of a gene (192). Enzymatically, histone
methylation is controlled by histone methyltransferase
(HMTs) specific to K and R residues (312), as well as by
histone demethylases (HDMs) such as peptdidylarginine
deiminase (PADI), jumonji-C domain containing histone
demethylases (JMJCs), and lysine-specific demethylases
(LSDs) (168).
C) PHOSPHORYLATION. Histone phosphorylation occurs
on serine (S), threonine (T), and tyrosine (Y) residues and
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FIG. 3. The nucleosomal core particle and the most common posttranslational histone modifications. A, left: X-ray crystallographic represen-
tation of the nucleosome heteroctameric protein core with DNA wrapped around it. Histone components are visualized by electrostatic surface
representation and have been color-coded for ease of viewing: histone H2A, blue; histone H2B, yellow; histone H3, green; histone H4, red. DNA is
represented in stick and ball format and is colored gray. Right: schematic representation of the figure at left, utilizing identical color-coding schemes.
[Adapted from Luger et al. (208), with permission from Nature Publishing Group.] B: stick illustrations of the major histone posttranslational
modifications covered in this review. The unmodified side chain of posttranslationally modifiable residues is first presented, followed by
representations of the residue on which the posttranslational modification has occurred at respective sites. Abbreviations are as follows: K, lysine;
R, arginine; Y, tyrosine; S, serine; T, threonine; -ac, acetylation; -me, monomethylation; -me2, dimethylation; -me3, trimethylation; -ph, phosphor-
ylation. The color code is as follows: yellow, carbon; blue, nitrogen; pink, polar hydrogen; red, oxygen; orange, phosphorus; green, methyl groups
of posttranslational modifications. [Modified from Taverna et al. (335), with permission from Nature Publishing Group.]
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is most commonly associated with transcriptional activa-
tion (203), because the negative charge of the phosphate
group creates a repulsive force between the histone and
the negatively charged DNA (Fig. 3C). Histone phosphor-
ylation is regulated by protein kinases (PKs) and protein
phosphatases (PPs) (116). Histone phosphorylation is
perhaps the most intriguing histone modification in the
CNS insofar as it establishes a direct link between the
epigenetic machinery and important intraneuronal signal-
ing pathways that heavily utilize protein kinases and phos-
phatases (189).
D) UBIQUITINATION. Histone ubiquitination refers to the
attachment of the 76-amino acid protein ubiquitin to the
histone core proteins H2A and H2B. H2A and H2B ubiq-
uitination have different consequences on the transcrip-
tion of the gene on which they are located. Whereas H2A
ubiquitination is considered repressive, H2B ubiquitina-
tion has been associated with both active and repressed
genes (357). Interestingly, H2A and H2B ubiquitination
and histone methylation often cross-talk, in particular via
H3K4 di- and trimethylation. H2B ubiquitination is
thought to be a prerequisite for H3 methylation, but H2A
inhibits this methylation (312, 357).
E) SUMOYLATION. Lastly, histones can be sumoylated.
SUMO proteins are similar to ubiquitin, roughly 100 amino
acids long and added to their targets by specific ligases,
the actions of which are reversed by proteases (103).
Histone sumoylation is a mark of transcriptional repres-
sion (252, 311), because of its interaction with other re-
pressor complexes and by its prevention of histone acet-
ylation (103).
2. Histone variants
Histone variants result from sequential and structural
variations of the core histones. These variations can com-
prise the replacement of large groups of amino acids in
the histone tails, in the globular central domains, or entail
only a few amino acid substitutions (192). Whereas the
four core histones are incorporated into the nucleosomal
structure exclusively during DNA replication, histone
variants can be integrated into specific regions of the
genome throughout the cell cycle. Their integration can
then alter the local regulation of gene transcription (275,
333). Because the core histones and their variants are
structurally similar, they can be readily exchanged, al-
though the precise mechanisms behind this operation are
not fully understood.
In some cases, single histones, or even entire histone
octamers, can be displaced in a phenomenon termed
“histone eviction,” which has a profound impact on the
compaction of chromatin and, thus, on gene transcription
(192).
C. Nucleosome Remodeling
Nucleosome remodeling refers to the process by
which change in the structure of chromatin is produced
and which requires a net energy input. Nucleosome re-
modeling is carried out by enzymes that are catalytically
dependent on ATP as an energy source. In eukaryotes,
these enzymes are defined by containing the SWI/SNF
subunit of ATPases (79). With ATP as a substrate, they
facilitate the sliding of histone octamers to adjacent DNA
sequences and thereby the enrichment of accessible DNA
on the surface of nucleosomes (for a review, see Ref. 19).
With all these levels of possible epigenetic modifica-
tions, it is important to realize that epigenetic mecha-
nisms are part of a highly complex and interwoven net-
work, including multiple positive and negative feed-for-
ward and feedback pathways (e.g., Refs. 43, 181, 183) that
span both the DNA and the histone level as well as higher
order chromatin structure. As a result, on many occa-
sions, several epigenetic modifications are found to be
jointly altered, although the precise mechanisms behind
these observations remain only poorly understood.
III. PHYSIOLOGICAL FUNCTIONS OF
EPIGENETIC REGULATION IN THE CNS
The epigenetic regulation of gene expression plays
an important role in such diverse processes as the devel-
opment and differentiation of the nervous system, synap-
tic plasticity, learning and memory, as well as the main-
tenance and survival of neurons. In the following sections,
we describe in detail the implications of epigenetic mech-
anisms for each of these physiological processes.
A. Development of the Nervous System and
Cellular Differentiation
Any given tissue of an organism consists of specific
cell types that have acquired precise and well-defined
functions during development, a process called differen-
tiation. Differentiated cells originate from a common pre-
cursor cell through the activation of genes important for
that given tissue, and the silencing of genes that are not.
Epigenetic mechanisms regulating gene expression arose
as potential candidates to confer such tissue-specific gene
expression (193). Indeed, Waddington himself in 1957 had
already proposed that a cell differentiates into its final
destination by taking specific paths throughout the “epi-
genetic landscape” (352, reviewed in Ref. 317; Fig. 4A).
This is also true for the nervous system and its three
major cell types: neurons, astrocytes, and oligodendro-
cytes. These cell types have their origin in neural stem
cells (NSC), multipotent, predifferentiated stem cells that
will develop into neuronal and glial lineages, but that
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FIG. 4. Epigenetic mechanisms in the development of the nervous system. A: a drawing by the developmental biologist Conrad Hal Waddington
(1905–1975) depicting his vision of an “epigenetic landscape.” The ball represents a cell, which has the potential to travel along various
developmental “valleys,” i.e., paths. These valleys are surrounded by hills that are made up of specific epigenetic codes and thus define the
developmental trajectory. In the case of the nervous system, this cell would be a neuronal stem cell. [From Slack (317), with permission from Nature
Publishing Group.] B: schematic illustrating an example of epigenetic mechanisms at play during neuronal development. Left: future non-neuronal
cell types, e.g., epithelial cells, are characterized by the binding of the transcriptional repressor REST to the NRSE element in the promoter region
of neuronal genes such as BDNF. This binding subsequently triggers the recruitment of an epigenetic silencing machinery constituted by MeCP2 as
well as HDACs, which increase DNA methylation and decrease histone acetylation, respectively. As a result, neuronal genes are silenced in
nonneuronal cell types. Right: in neurons, REST is not active and neuronal genes can be transcribed. C: schematic illustrating an example of
epigenetic mechanisms at play during astrocyte development. Left: in non-astrocytic cell types such as neurons, the promoter region of the
astrocyte-specific gene GFAP is highly methylated and bound by MeCP2 and MBP proteins, which prevents the transcription factor STAT3 from
binding and GFAP from being expressed. Right: during astrocyte differentiation, the STAT3 binding site is no longer methylated, but instead its
histones hyperacetylated by p300 and CBP, which allows STAT3 to bind and GFAP expression to occur. D: schematic illustrating two examples of
epigenetic mechanisms at play during oligodendrocyte development. Unlike neurons and astrocytes, the differentiation of oligodendrocytes is
characterized by an overall decrease in histone acetylation, which has been shown to occur on non-oligodendrocyte-specific transcriptional
activators, and on oligodendrocyte-specific transcriptional repressors. Both mechanisms allow for the expression of oligodendrocyte-specific
transcriptional programs. Note that histone methylation is also involved in this process, but not depicted here. See text for gene names and more
details.
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retain the ability to self-renew (100). During neurodevel-
opment, neurons differentiate first, followed by astro-
cytes and oligodendrocytes during late gestation (336).
Therefore, during the course of early and midgestation,
only neuronal genes must be active in the pool of neuro-
nal stem cells that are later to become fully differentiated
neurons.
1. Neural differentiation
The best-described pathway guiding neural differen-
tiation involves the selective inactivation of neuronal
genes in non-neuronal tissue via the regulatory element
neuron-restrictive silencer element (NRSE) in their pro-
moter region (241) (Fig. 4B). The NRSE is a 21- to 24-bp-
long sequence present upstream of the start codon of
neuronal genes, which was first described to silence the
expression of the type II sodium channel in non-neuronal
cultured rat cells, and of the synapsin I gene in human cell
lines (195, 223). The precise functioning of this element
remained, however, unclear, although it was speculated
that the NSRE acts through the additional binding of
transcriptional repressors (241).
The first such repressor identified to bind the NRSE
was RE1-silencing transcription factor (REST) (57). The
in vitro expression of a recombinant REST protein in
neuronal cells, which normally lack the native REST pro-
tein, resulted in increased silencing of neuronal genes.
Conversely, the expression of a dominant-negative form
of REST in non-neuronal cell types abolished the silenc-
ing function of the normal protein (57). The deletion of
REST during embryonic development in vivo further
caused a derepression of neuron-specific genes in non-
neuronal cell types and led to embryonic lethality (52).
Accordingly, the overexpression of REST in the develop-
ing spinal cord of chicken embryos led to increased axon
guidance errors due to erroneous gene expression, and
consequently to developmental dysfunctions (264). Thus
REST-dependent gene silencing has been shown in vitro
and in vivo to be a factor determining neuronal cell
fate (17).
REST-mediated gene repression involves epigenetic
modifications, since the NRSE sequence not only recruits
REST, but also several corepressors. Among these core-
pressors is methyl-CpG-binding protein 2 (MeCP2), and
DNA methylation in the promoter region of various genes
such as sodium channel type II, brain-derived neu-
rotrophic factor (BDNF), and calbindin has been shown
to be required for their transcriptional silence (16, 209).
Remarkably, this DNA methylation does not seem to be
confined to the actual NRSE sequence alone, but extends
several thousand base pairs up- and downstream of the
NRSE region, indicating a silencing effect that includes
neighboring genes (209). Of note, REST binding to the
NRSE in the promoter region of calbindin was further
decreased when sources of maternal choline were re-
stricted, which led to increased expression levels of cal-
bindin and disrupted neural development (230). This ef-
fect was accompanied by decreased H3K9 methylation
and increased DNA methylation, suggesting a hitherto
unidentified cross-talk between histone and DNA methyl-
ation during neural differentiation.
In addition to REST, other corepressors associated
with the NRSE element include mSin3 and CoRest (9, 139,
251), which complex with HDACs type I and type II,
respectively (15, 139, 251, 290). These findings suggest
that NRSE/REST-mediated gene silencing in developing
nonneuronal cells requires both decreased histone acety-
lation and increased DNA methylation, two epigenetic
modifications that condense the chromatin.
But also outside the NRSE/REST pathway does chro-
matin remodeling, in particular chromatin decondensation at
neuron-specific genes play a role in neural development. For
instance, treatment of NSCs with HDAC inhibitors (HDACis)
such as [N-(2-aminophenyl)-4-N-(pyridine-3-ylmethoxy-
carbonyl)aminomethyl]benzamide (MS-275) and suberoyla-
nilide acid (SAHA) promoted neural differentiation via
increased expression levels of the neuron-specific tran-
scription factor NeuroD (314). NeuroD is also stimulated
by the HAT complex p300/CREB-binding protein (CBP)
that is regulated by neurogenin (324). Likewise, neuron-
specific transcriptional activity of the inhibitor of cyclin-
dependent kinase I (Cdkn1c) is accompanied by elevated
H3K9/K14 acetylation levels (12). Most likely, these ef-
fects are the result of the concerted action of decreased
HDAC activity and increased HAT activity in differentiat-
ing neurons. Correspondingly, leucine-rich acidic nuclear
protein (LANP), a member of the inhibitor of HAT com-
plex (INHAT), constrains neurite outgrowth, which is
accompanied by reduced histone acetylation at the neu-
rofilament light chain (NFL) promoter (174). Neural dif-
ferentiation appears, therefore, to be characterized by
elevated histone acetylation levels at neuron-specific
genes.
Similarly, the patterns of histone methylation at neu-
ron-specific genes also seem to reflect chromatin-relaxing
mechanisms. Two recent studies found that H3K4 dim-
ethylation, a marker of transcriptional activity, was en-
hanced in the promoter region of neuron-specific opioid
receptors, whereas H3K9 trimethylation, a marker of tran-
scriptional repression, was reduced (51, 265). Another
study found that the histone H3K27-specific histone
demethylase JMJD3 is necessary for neural differentia-
tion, as it demethylates H3K27, a modification indicat-
ing transcriptional repression, at the neuron-specific
nestin promoter (38).
Furthermore, several studies indicate that DNA
methylation in NSCs needs to be reduced for neural com-
mitment to occur. A deficiency in methylated CpG binding
protein 1 (MBD1), a member of the MBPs, promoted
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increased neural differentiation of NSCs, presumably via
the reduced repression of fibroblast growth factor 2
(FGF2), which maintains NSCs in their multipotent state
(196). Likewise, reduced DNA methylation, and a con-
comitant increase in histone acetylation, were also de-
tected in the enhancer regions of SOX2 in proliferating
NSCs (315).
These findings suggest that the expression of neuron-
specific genes during neural commitment is guaranteed
by an overall relaxation of the chromatin structure via
increased histone acetylation, residue-specific histone
methylation changes, and decreased DNA methylation. At
least in the case of DNA methylation, however, it has to be
noted that a reduction in DNA methylation is only bene-
ficial for neural differentiation when it occurs on neuron-
specific genes. A recent study has indeed found that the
hypomethylated cortical neurons of conditional DNMT1
knockout mice exhibit impaired neuronal excitability and
increased neuronal cell death (141). In addition, shRNA-
mediated silencing of DNMT3b also reduced neuronal
differentiation (14). It is therefore important to extend the
existent examples to genome-wide epigenetic analyses to
prove their overall validity. In this respect, it will be of
great value to compare the epigenomic and transcription
profiles between NSCs and fully differentiated cells of the
nervous system, and also between differentiated cell
types.
Lastly, it remains to be noted that the composition of
core histone variants also changes during neural differen-
tiation (31), but the functional consequence of this change
remains unknown.
2. Astrocytic differentiation
Astrocyte differentiation occurs during late gestation
and is characterized by the activation of the transcription
factor Janus kinase signal transducer and activator of
transcription 3 (STAT3) (16). Activated STAT3 binds to
the promoter regions of astrocyte-specific proteins such
as glial fibrillary acidid protein (GFAP) and induces their
expression (Fig. 4C). Several studies imply a role for
epigenetic mechanisms in governing GFAP expression.
During early and mid-gestation, the STAT3-binding ele-
ment in the GFAP promoter is methylated, preventing
STAT3 from binding and the astrocytes from differentiat-
ing (332). Accordingly, the conditional knock-out of
DNMT1 in NSCs resulted in precocious astrocytic differ-
entiation (81). GFAP expression is further absent from
differentiated neurons, in which the STAT3 element is
also methylated and bound by MeCP2 and MBPs (250).
Importantly, as a recent genome-wide DNA methylation
profiling study revealed, DNA methylation until midgesta-
tion is not restricted to genes containing a STAT3 ele-
ment, but also occurs on other astrocyte-specific genes,
such as the glial potassium channel KCNJ10 (130).
In addition to DNA demethylation, chromatin-decon-
densing histone PTMs are also implicated in regulating
GFAP expression in astrocytes. During astrocytic differ-
entiation, the HAT CBP is recruited to the STAT3-binding
element in the GFAP promoter by fibroblast growth factor
2 (FGF2), which is accompanied by increased H3K4, and
decreased H3K9, methylation (332), markers of transcrip-
tional activation and repression, respectively (192). The
HAT p300 is also part of the transcriptional complex
responsible for the expression of GFAP during astrocytic
development (324). Remarkably, the same complex is
removed from the GFAP promoter during neural differ-
entiation (324), indicating a timely and highly orches-
trated employment of similar epigenetic mechanisms for
the differentiation of different cell types.
3. Oligodendrocytic differentiation
Oligodendrocytes, the myelin-producing cells of the
CNS, develop during late gestation and the early postnatal
period. Unlike neural or astrocytic differentiation, oligo-
dendrocytic differentiation is initiated by a global histone
deacetylation (217), which confers cell-lineage specificity
for developing oligodendrocytes. This deacetylation is
thought to operate via two mechanisms (62) (Fig. 4D). On
one hand, deacetylation has been shown to inhibit tran-
scriptional activators of other cell lineages such as the
glial-specific transcription factor Sox2 (212). On the other
hand, the same deacetylation operates to inhibit tran-
scriptional repressors of oligodendrocytic differentiation
such as SRY-box containing gene 11 (Sox11) (131). Ac-
cordingly, treatment of NSCs with the HDACis MS-275,
SAHA or valproic acid (VPA) led to a reduced proportion
of oligodendrocytes resulting from higher numbers of
neurons and astrocytes (198, 314). A recent report iden-
tified the types of HDACs involved in oligodendrocyte
differentiation (367). When both HDAC1 and HDAC2, but
not either enzyme alone, were deleted from the develop-
ing oligodendrocytic lineage, all oligodendrocytes were
lost, without the neuronal or astrocytic cell population
being affected. Mechanistically, the HDAC1/2 double loss-
of-function resulted in a stabilization of -catenin, a mem-
ber of the Wnt-signaling pathway, which negatively regu-
lates oligodendrocyte differentiation (313). These findings
therefore suggest redundant roles for HDAC1 and HDAC2
in the development of oligodendrocytes, which is in con-
trast to the roles of these two enzymes in learning and
memory (see sect. IIIC).
In addition to reduced histone acetylation, the differ-
entiation of oligodendrocytes is further characterized by
increased H3K9 dimethylation (309), another indicator of
transcriptional repression (192). Subsequently, histone
hypoacetylation and H3K9 hypermethylation have been
proposed to constitute an oligodendrocyte-specific “epi-
genetic memory” (310). Such a concept is in agreement
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with the notion of the “histone code” that stipulates that
different cell types are characterized by specific histone
modifications (150, 342), also within the CNS (189). As we
will see later, it is precisely this “epigenetic memory” that
can become severely disturbed during aging and disease.
4. Adult neurogenesis
Mammalian adult neurogenesis refers to the process
of the continuous production of new neurons in the sub-
ventricular zone and the subgranular layer (SGL) of the
dentate gyrus throughout life. The initial indication of the
involvement of epigenetic mechanisms in this process
came from mice lacking the transcriptional repressor
MBD1. These mice have decreased neurogenesis and in-
creased chromosomal instability in the SGL of the dentate
gyrus (369). In agreement with a role for DNA methylation
in adult neurogenesis, the growth arrest and DNA-dam-
age-inducible protein 45 (GADD45) was shown to act as
or to trigger the action of other demethylases (213).
GADD45 expression is induced by neuronal activity re-
sulting from behaviors such as the exploration of a novel
environment, or electroconvulsive treatment, and GADD45 ac-
tivity induces the proliferation of adult neuroprogenitors,
in part by reducing DNA methylation in the promoter
regions of BDNF and FGF1, two genes critical for neuro-
genesis.
Another hint that epigenetic mechanisms, this time in
terms of histone acetylation, are at play during adult
neurogenesis was the finding that administration of the
HDACi VPA blocked seizure-induced aberrant neurogen-
esis (151), but the identity of the relevant HDACs and the
precise histone acetylation changes have not yet been
elucidated. Remarkably, however, another HDACi, so-
dium butyrate (SB), was recently found to stimulate neu-
rogenesis under ischemic conditions (161). In these in-
stances of adult neurogenesis, therefore, changes in his-
tone acetylation seem to be important, but the relevant
mechanisms await further clarification.
Finally, a third line of evidence suggests a criticial
role for histone methylation in adult neurogenesis. Mixed-
lineage leukemia 1 (Mll1), a member of the evolutionarily
conserved trithorax group of transcriptional activators,
was found to directly bind to the promoter region of the
homeobox protein Dlx2, an important regulator of SGL
neurogenesis, where it elevated H3K4 trimethylation, a
marker of transcriptional activation (192), and increased
Dlx2 gene expression (197). Consistently, in Mll1-defi-
cient NSCs, Dlx2 expression was reduced, in part be-
cause, in addition to H3K4, the repressive chromatin
marker H3K27 was strongly increased in the promoter
region of Dlx2.
As the original purpose of epigenetic programs was
to promote differentiation and define cell fate during de-
velopment, which includes neurogenesis, future work is
likely to identify more chromatin-modifying enzymes and
other epigenetic mechanisms involved in promoting adult
neurogenesis.
B. Synaptic Plasticity
After its differentiation is complete, the CNS neuron
embarks on its various physiological functions. One im-
portant function is the regulation of synaptic plasticity,
i.e., the strengthening or weakening of synaptic connec-
tions following neuronal activation, often regarded as the
molecular correlate of learning and memory (363). Syn-
aptic plasticity has been most extensively studied in the
marine mollusk Aplysia californica as well as in the
mammalian hippocampus. Long-lasting forms of synaptic
plasticity have been shown to involve changes in the
expression of genes involved in synaptic functioning (for
review, see Ref. 273), and in recent years, evidence has
been accumulating that epigenetic mechanisms play crucial
roles in promoting these long-lasting changes (Table 1).
1. Non-mammalian synaptic plasticity
In Aplysia, the sensorimotor synapse shows two
forms of long-term synaptic plasticity. Long-term facilita-
tion (LTF), which is a lasting, often transcriptional-depen-
dent amelioration of transmission across synapses; and
long-term depression, which is a deterioration of such
transmission. Importantly, the same synapse can be the
site of both forms of synaptic plasticity, and therefore
requires an inducible, reversible, and bidirectional molec-
ular “switch” mechanism. In an elegant study using cul-
tured sensory-motor neurons of Aplysia, Guan et al. (122)
have shown that the increase and decrease of acetylated
histones might constitute such a switch. Long-term facil-
itation was accompanied by increased binding of the HAT
CBP to the promoter region of C/EBP, a gene downstream
of the CREB transcription factor. Concurrently, H3K14
and H4K8 acetylation, as well as the transcriptional rate
of C/EBP, were increased. Long-term depression, on the
other hand, was correlated with the opposite effects, in
part through the recruitment of HDAC5. Interestingly,
administration of the HDAC inhibitor trichostatin A (TSA)
resulted in a switch from short- to long-term facilitation
upon the same electrical stimulation, suggesting that a
global change in acetylation can modify synaptic plastic-
ity in invertebrates.
2. Mammalian synaptic plasticity
In mammals, the molecular correlate of long-term
memory is termed long-term potentiation (LTP), which is
an increase in the efficiency of synaptic transmission as a
result of high-frequency stimulation (for a review, see Ref.
28). In the hippocampus, various signaling pathways, in-
612 GRA¨FF, KIM, DOBBIN, AND TSAI
Physiol Rev • VOL 91 • APRIL 2011 • www.prv.org
volving dopaminergic, acetylcholinergic, and glutamater-
gic signaling, have been implicated in synaptic plasticity
(30, 96, 140). When these three pathways were individu-
ally stimulated by the systemic administration of the re-
ceptor-specific drugs SKF82958 (a dopaminergic receptor
agonist), pilocarpine (a muscarinic acetylcholine receptor
agonist), and kainate (a kainate glutamate receptor agonist),
respectively, mouse hippocampi displayed increased
H3S10 phosphorylation and H3K14 acetylation. This cor-
related with an increased expression of the immediate
early gene FBJ osteosarcoma oncogene (c-fos), in the
promoter region of which these epigenetic modifications
were found (68). Interestingly, changes in the pattern of
H3 phosphorylation paralleled those in the phosphoryla-
tion of the extracellular regulated kinase (ERK), a member of
the mitogen-activated protein kinase (MAPK) pathway, a
signaling cascade implicated in different forms of memory
and synaptic plasticity (reviewed in Ref. 328). Further-
more, activation of ERK through the protein kinases PKC
and PKA also increased H3K14 acetylation, and activation
of N-methyl D-aspartate (NMDA) receptors resulted in a
similar increase of acetylated H3, which could be blocked
by inhibition of the ERK signaling (187). These studies
provided the first evidence that the intracellular signaling
ERK/MAPK pathway also interacts with the epigenetic
machinery to modulate synaptic plasticity.
Importantly, acetylation changes appear to be an in-
tegral part of synaptic plasticity, as administration of the
HDAC inhibitors TSA and SB enhanced the induction of
LTP in wild-type rats (187). This was further confirmed in
mice lacking the HAT CBP (CBP/) or its HAT domain
(CBP1) (6, 365). CBP/ mice show a decrease in the
overall acetylation of H2B, and the induction of the tran-
scription-dependent late-phase LTP in hippocampal slices
was significantly impaired, whereas the transcription-in-
dependent early-phase LTP was not changed. Treatment
with the HDACi SAHA ameliorated the defects in late-
phase LTP (6). Similarly, CBP1 mice show impaired
late-phase LTP, while the early phase of LTP is unaffected
(365). These genetic and pharmacological studies suggest
a direct link between the levels of histone acetylation and
late-phase LTP performance, and the rescue of late-phase
LTP with HDAC inhibition.
Two recent studies have now revealed the identity of
at least one HDAC that is causally regulating LTP forma-
tion (121) and thus emerges as a potential target of HDAC
inhibition. HDAC2, but not the structurally highly related
HDAC1, impairs LTP formation in the adult hippocampus,
TABLE 1. Epigenetic mechanisms in synaptic plasticity
Context Epigenetic Modification Mechanism Organism Brain Area Reference Nos.
Synaptic plasticity Histone acetylation CBP-induced H3K14 and H4K8 hyperacetylation
on C/EBP accompany LTF
Aplysia Sensory-motor neurons 122
TSA increases LTP Rat Amygdala 368
ERK/MAPK activity leads to H3K14
hyperacetylation
Rat Hippocampus 187
CBP deficiency results in H2B hypoacetylation
and late-phase LTP impairment
Mouse Hippocampus 6, 365
PcG protein Mll-deficiency enhances, TrxG
protein EED-deficiency impairs LTP
Mouse Hippocampus 166
TSA enhances LTP and transcription of CRE-
containing genes
Mouse Hippocampus 348
PKC activation enhances LTP and H3K14
acetylation
Rat Hippocampus 235
HDAC2 overexpression impairs, HDAC2 k.o.
enhances LTP
Mouse Hippocampus 121
DNA methylation MBD1 deficiency leads to reduced LTP Mouse Hippocampus 369
Inhibition of DNMT1 activity by 5-aza blocks
LTP
Mouse Hippocampus 188
5-Aza and zebularine reduce mEPSCs and
increase BDNF DNA methylation and
transcription
Mouse Hippocampus 253
Double knock-out of Dnmt1 and Dnmt3a
impairs synaptic plasticity
Mouse Forebrain 86
Seizures Histone acetylation Pilocarpine-induced seizures lead to H4
hypoacetylation of GluR2
Rat Hippocampus 138
Acute and chronic electroconvulsive seizures
induce differential H3 and H4 acetylation
Rat Hippocampus 341
BDNF, brain-derived neurotrophic factor; CBP, CREB-binding protein; CRE, CREB-response element; C/EBP, CCAAT/enhancer-binding protein;
DNMT1, DNA methyltransferase 1; ERK/MAPK, extracellular regulated kinase/mitogen-activated protein kinase; GluR2, glutamate receptor 2; H,
histone; HDAC2, histone deacetylase 2; K, lysine; k.o., knock-out; LTF, long-term facilitation; LTP, long-term potentiation; MBD1, methyl-CpG
binding protein 1; mEPSC, miniature excitatory postsynaptic current; PcG, polycomb-group; PKC, protein kinase C; S, serine; TrxG, trithorax-group;
TSA, trichostatin A; 5-aza, 5-aza-2-deoxycytidine.
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as mice with neuron-specific overexpression of HDAC2
exhibited decreased postsynaptic currents, whereas HDAC1
overexpressing mice did not (121). In line, neuronal cul-
tures with a loss-of-function allele of HDAC2, but not
HDAC1, showed facilitated synaptic transmission plus an
increase in synapse numbers (5). Remarkably, during neu-
ronal development, both HDAC1 and HDAC2 loss-of-
functions result in facilitated synaptic transmission (5),
pointing to a developmental switch in the expression
and/or importance of HDAC1 and HDAC2. In adulthood,
the specificity of HDAC function appears to be mediated
by the preferential binding of HDAC2, but not HDAC1, to
genes involved in synaptic plasticity such as PKM, Cdk5,
or NMDA receptors (121).
Members of the Polycomb (PcG) and trithorax (trxG)
group proteins, which are crucial epigenetic regulators of
developmental gene expression, also impact synaptic
plasticity. Mice with a heterozygous deletion for eed, a
member of the transcriptional repressor PcG family, dis-
play enhanced LTP, whereas mice heterozygous for Mll, a
member of the transcriptional activator trxG family, have
decreased hippocampal LTP, the latter finding correlating
with an overall hypoacetylation of H4 (166).
Similar to the hippocampus, administration of the
HDACi TSA into the rat amygdala increases LTP (368),
confirming the importance of histone acetylation in dis-
tinct brain areas. Remarkably, however, such administra-
tion of an HDAC inhibitor does not alter the epigenome
globally, but site-specifically (348). Upon application of
TSA to hippocampal slices of fear-conditioned animals,
only a subset of CRE-containing genes was shown to be
transcriptionally upregulated. This effect was CREB de-
pendent, since no such upregulation was observed in
mice with targeted deletions of the alpha and delta iso-
forms of CREB (348). Although this study specifically
focused on the CREB signaling pathway, which is one of
the most prominent pathways regulating gene expression
changes in synaptic plasticity, its findings are of broad
interest, as they indicate gene-specific actions of HDACis,
although the mechanisms underlying this target specific-
ity remain unidentified. Genome-wide binding studies of
the different classes of HDACs should resolve this ques-
tion.
Alongside histone posttranslational modifications,
DNA methylation constitutes another epigenetic mecha-
nism that regulates synaptic plasticity. Mice lacking the
methylated DNA-binding transcriptional repressor MBD1
display reduced hippocampal LTP (369), which presum-
ably occurs through the aberrant gene expression of plas-
ticity-related genes. LTP induction is efficiently blocked
when mouse hippocampi are treated with zebularine and
5-aza-2-deoxycytidine (5-aza) (188), two potent inhibitors
of DNMT activity. Additionally, activation of PKC through
the administration of phorbol esters led to a decrease in
the methylation of the promoter region of reelin, a gene
implicated in the induction of synaptic plasticity in the
hippocampus, as well as to an upregulation of gene ex-
pression of c-fos (188). This finding suggested, for the first
time, that DNA methylation, long considered to be a sta-
ble epigenetic mark, is both dynamically regulated and
involved in mammalian synaptic plasticity. Interestingly,
PKC activation also led to increased H3K14 acetylation,
which could be blocked by zebularine treatment (235),
thus providing a hitherto unknown link between dynamic
DNA methylation and histone acetylation in LTP forma-
tion.
A recent study has now identified at least two en-
zymes responsible for maintaining DNA methylation in
adult neurons, Dnmt1 and Dnmt3a (86). Interestingly,
neuron-specific knockout of either of these enzymes
alone had no effect on LTP and spatial memory, suggest-
ing a redundant role for these enzymes on synaptic plas-
ticity in the adult brain.
Lastly, LTP is not the only form of synaptic plasticity
that is modulated by epigenetic mechanisms; the same
applies to miniature excitatory postsynaptic currents
(mEPSCs), which result from the temporary depolariza-
tion of postsynaptic membranes by small amounts of
released neurotransmitters. Treatment of mouse hip-
pocampal cultures with the DNMT inhibitors 5-aza and
zebularine resulted in decreased mEPSCs, which was ac-
companied by increased DNA methylation of the BDNF
gene promoter 1 and enhanced BDNF gene expression
(253).
3. Seizures
Seizures may be considered as an extreme case of
synaptic plasticity, since they occur following excessive
electrical activity in the CNS. Seizures can be experimen-
tally induced both chemically and electrophysiologically,
and both types of induction alter the expression of a
variety of genes, including the glutamate receptor 2
(GluR2) and BDNF (reviewed in Ref. 190). Chemically
induced seizures, using the muscarinic acetylcholine re-
ceptor agonist pilocarpine, downregulated GluR2 expres-
sion, and this correlated with decreased H4 acetylation on
the GluR2 promoter (138). Treatment of rat hippocampal
slices with TSA reversed this hypoacetylation and, in
parallel, upregulated BDNF expression, which correlated
with H4 hyperacetylation of the BDNF P2 promoter.
Epigenetic changes are also observed following elec-
troconvulsive seizures (ECS) (341). After ECS, H4 acety-
lation in the promoter region of the c-fos, BDNF, and
CREB genes correlated with altered mRNA levels, dis-
playing hyperacetylation of the promoters with increased
gene expression, and vice versa. However, no such clear
correlation could be drawn for the acetylation (K9 and
K14) and phosphoacetylation (S10 and K14) levels of H3,
suggesting a more general role for H4 acetylation and a
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more specific, albeit unknown role, for H3 acetylation and
phosphorylation, in seizure-induced plasticity. Of note,
there appears to be a difference in the epigenetic mech-
anisms induced by acute versus chronic ECS. Whereas H4
acetylation changes were observed both upon acute and
chronic ECS in the promoters of BDNF (P2), c-Fos, and
CREB, H3 acetylation changes were observed only during
chronic ECS, at least for BDNF (341). These results sup-
port the increasing body of evidence that manifold forms
of synaptic activity result in specific and complex epige-
netic tagging of histones that influence gene expression.
But they also emphasize that more detailed studies are
required to elucidate these mechanisms.
C. Learning and Memory
As with long-lasting forms of synaptic plasticity, long-
term memories require stable gene expression changes
(153). Hence, epigenetic mechanisms remodeling the
chromatin structure at genes important for learning and
memory are likely candidates to guarantee such enduring
changes (Table 2).
1. Novel taste learning
The first indication that epigenetic modifications
might be involved in memory formation stems from a
study addressing the molecular correlates of novel taste
learning in the insular cortex, a brain region important for
taste memories. Treatment of insular cortex slices with
the HDAC inhibitor TSA resulted in increased acetylation
of histones H2A and H4, whereas H2B and H3 acetylation
remained unchanged (326). Novel taste learning was fur-
ther associated with an increased phosphorylation of
MAPK, an indication of increased MAPK activity, suggest-
ing that the ERK/MAPK pathway might be involved in
regulating histone acetylation. Although the precise
mechanisms relating ERK/MAPK activation to alterations
in histone acetylation still remain unknown, it is possible
that MAPK interacts with enzymes that modify histone
acetylation and thus, indirectly, triggers the observed
changes. As we will see in the next section, such a cas-
cade was indeed observed for the molecular counterpart
of protein kinases, protein phosphatases.
2. Spatial memory
There is ample evidence that histone acetylation,
phosphorylation, and methylation, as well as DNA meth-
ylation, are implicated in spatial memory formation, and
indeed, several enzymes promoting these epigenetic mod-
ifications have been identified. Spatial memory formation
depends on the hippocampus (242), and all molecular
results described herein are located within this brain
region.
The first reports relating histone acetylation to spatial
memory addressed the role of the HAT CBP. While Alar-
con et al. (6) used mice heterozygous for CBP (CBP/), Kor-
zus et al. (170) tested mice with point mutations in the
CBP HAT domain (CBP/HAT) with no HAT function.
Intriguingly, however, spatial memory, as assessed by the
Morris water maze, was only impaired in CBP/HAT mice
(170), but unaffected in CBP/ mice (6). This suggests
that some compensatory effect might be at play in the
mouse model with the more substantial CBP decrease. In
the CBP/HAT mice, administration of the HDACi TSA
was shown to rescue the spatial memory deficits, which
correlated with increased H3 acetylation levels (170).
Mice completely lacking the HAT domain of CBP
(CBP1), which showed equally impaired spatial memory
(365), corroborated these findings. In contrast, however,
mice lacking the HAT domain of another HAT, p300
(p3001), had normal spatial, but impaired object mem-
ory (259). This may again point to unidentified compen-
satory mechanisms at play, or alternatively, to the specific
employment of different HATs for different forms of
memory.
In addition to HATs, several studies have demon-
strated a role of their molecular counterparts, the HDACs,
in spatial memory. While the HDACi TSA rescued spatial
memory deficits in the CBP/HAT mice (170), the HDACi
SB had the same effect in mice following traumatic brain
injury (72), and in the CK-p25 mouse model of neurode-
generative disease (92), which is characterized by im-
paired synaptic plasticity and memory (69, 91). Recently,
Guan et al. (121) demonstrated that these effects are most
likely due to HDAC2, and not HDAC1, as mice overex-
pressing HDAC2 (but not HDAC1) had impaired spatial
memory (121).
In addition to histone acetylation, histone phosphor-
ylation and methylation have lately also been identified as
histone PTMs relevant for spatial memory. H3S10 phos-
phorylation (but not H3T3, H3T11, and H3S28 phosphor-
ylation) as well as H3K36 trimethylation (but not H3K4
dimethylation) were upregulated in mice with enhanced
spatial memory caused by the inhibition of nuclear pro-
tein phosphatase 1 (PP1) (171), a molecular constraint of
learning and memory (108). These modifications resulted
from the reduced binding of PP1 to the chromatin, and a
reduced interaction between PP1 and JMJD2A, an H3K36-
specific HDM, whereas the interaction between PP1 and
lysine-specific demethylase 1 (LSD1), an H3K4-specific
HDM, was unperturbed (171). Importantly, the findings
that spatial learning induces H3 phosphorylation, together
with H3 and H4 acetylation, were recently independently
confirmed in both mice and rats (286).
Finally, one study indirectly reported a role for DNA
methylation in spatial memory, as mice lacking MBD1 did
not remember the location of the platform on the Morris
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water maze (369). The underlying mechanisms, however,
remain unknown.
3. Fear memory
Direct evidence that DNA methylation is, indeed,
involved in memory formation and maintenance was ob-
tained by three studies addressing fear memory. In the
first, contextual fear conditioning was shown to be asso-
ciated with increased DNMT3a and DNMT3b expression,
accompanied by increased promoter methylation and de-
creased transcription of the memory suppressor gene PP1
(237). Conversely, the extracellular matrix and memory-
promoting gene reelin displayed decreased promoter
methylation, and increased transcription levels. Impor-
tantly, DNMT inhibition by 5-aza and zebularine erased
PP1 hypermethylation, elevated PP1 transcription, and,
consequently, impaired fear memory. In the second study,
similar results were obtained for BDNF and its promoter
region (205). Thus hippocampal BDNF exon IV expres-
sion was increased after contextual fear conditioning,
which was associated with decreased BDNF P4 promoter
methylation. H3 phosphoacetylation (assessed with a
H3S10/H3K14 pospho/acetyl-specific antibody) was also
increased at the BDNF P4 promoter after learning, which
is indicative of a reenforcing cross-talk between DNA
methylation and histone acetylation. Unexpectedly, zebu-
larine treatment, in conjunction with contextual fear con-
ditioning, led to no further DNA hypomethylation in
BDNF P4, but rather a reversal of the acetylation changes
and a deterioration of memory performance (205). Like-
wise, another study found that DNMT inhibition via 5-aza
led to a decrease in H3 acetylation (235). However, if DNA
methylation and histone acetylation are to work in con-
cert to regulate gene expression changes, as observed in
other model organisms (147), the opposite would have
been expected. There is no clear-cut explanation for this
finding, but since DNMTs not only regulate DNA methyl-
ation, but also DNA demethylation (234), and DNA meth-
ylation at promoter region is a highly dynamic phenome-
non occurring in cycles (154), zebularine treatment might
have far more complex consequences than expected. Al-
ternatively, compensatory mechanisms might also be at
work.
Lastly, in the third and most recent study, fear con-
ditioning-induced DNA methylation marks were still pres-
ent in the prefrontal cortex 30 days after the learning
event (236), where they efficiently silenced the expression
of the memory suppressor gene calcineurin. This finding
indeed suggests that DNA methylation could serve as a
stable mnemonic mark.
Several other studies have shown a role for histone
acetylation and phosphorylation in fear memory. For ex-
ample, contextual fear memory formation is associated
with increased overall H3 acetylation, which is paralleled
by the activation of the ERK/MAPK signaling cascade
(187). Latent inhibition, in contrast, is associated with
overall H4 hyperacetylation (187), indicating the possibil-
ity that different histone codes underlie different types of
memories (189). In addition, contextual fear conditioning
led to a transient increase in both H3S10 phosphorylation
and H3 acetylation, which again correlated with the acti-
vation of ERK (59) identifying, at least indirectly, ERK as
a histone kinase. Mice lacking mitogen and stress-acti-
vated kinase 1 (MSK1) showed impaired fear memory and
reduced histone phosphorylation and acetylation levels
(58), thereby defining MSK1 as another histone kinase
that controls histone phosphorylation as well as acetyla-
tion. A third member was added to the “family” of histone
kinases, the inhibitor B kinase  (IKK) (206), which is
part of the NfB pathway. Accordingly, retrieval of con-
textual fear led to the activation of IKK and a concom-
itant increase in H3 phosphoacetylation.
Several HDACis have proven useful for the enhance-
ment of conditioned fear memories. TSA enhanced con-
textual fear memory and increased H3 acetylation levels
(348) in wild-type mice, and VPA and SB administration
enhanced contextual fear learning in wild-type and trau-
matic brain-injured mice, respectively (34, 72). Further-
more, SB injections facilitated contextual fear condition-
ing in both wild-type and neurodegenerative CK-p25 mice,
and concomitantly elevated both H3 and H4 acetylation
levels (92).
Interestingly, VPA as well as SB and TSA also facili-
tated extinction and reconsolidation (34, 182), which can
be interpreted as relearning or the original memory trace
(246). In contrast to the effect of HDACi administration
for the facilitation of contextual fear learning, the VPA-
facilitated extinction of contextual fear was associated
with increased H4, but not H3 acetylation levels, at the
BDNF promoter P4 (35). This finding indicates once more
potentially different roles of these two acetylation modi-
fications in different memory tasks or phases. The diverg-
ing results in terms of H3 acetylation might also be ex-
plained by the use of different types of HDACis that have
different half-lives and different substrate specificity (128,
156). Clearly, more refined HDACi assessment is still
needed to confidently identify memory-type specific his-
tone codes.
Two more enzymes of the acetylation machinery
have been reliably shown to regulate fear memories: the
HAT CBP (365) and HDAC2 (121). CBP1 mice had im-
paired contextual fear memory, whereas HDAC2 condi-
tional knockout mice excelled over their control litter-
mates (and over HDAC2-overexpressing mice) in fear
remembrance. In the case of HDAC2, this memory im-
provement can likely be explained by the specific binding
of HDAC2 to important memory-related genes such as
c-Fos or BDNF, where it induces significant H3 and H4
deacetylation (121), and, presumably, gene silencing.
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Lastly, histone methylation has long been an epige-
netic candidate to be associated with fear memories, but
until recently, evidence for this has been completely lack-
ing. Recently, however, the first HMT to be implicated in
fearful memories has been identified (126, 301). Neuron-
specific deficiency of the HMT complex G9a-like protein
(GLP)/G9a in mice resulted in impaired cued and contex-
tual fear conditioning, which was accompanied by de-
creased H3K9 dimethylation in forebrain neurons. This
suggests that H3K9 dimethylation plays an important role
in contextual fear memories. Corroborating this notion,
another study found that hippocampal H3K9 dimethyla-
tion was upregulated 1 h after fear conditioning, in par-
ticular in the promoter region of the immediate early gene
Zif268 and Bdnf (126). Similar to H3K9, the methylation
of H3K4, in this case trimethylated H3K4, a mark of
transcriptional activity, was significantly enhanced at this
timepoint after contextual fear conditioning, and mice
lacking the H3K4-specific HMT Mll displayed fear memory
impairments (126). Surprisingly, these methylation marks
seem to be of a transient nature, as one day after fear
training, histone methylation levels were again at baseline
levels. Interestingly, the HDACi SB also altered the hip-
pocampal methylation profile, which is indicative of an
important cross-talk between histone acetylation and
methylation during fear memory formation. The precise
interplay between these two (and other) epigenetic “mne-
monic” marks remains to be determined.
4. Object memory
Histone acetylation also plays a role in object mem-
ory formation. Both CBP/ and p3001 mice have defi-
cits in long-term object memory as assessed by a novel
object recognition (NOR) task (6, 259), during which mice
have to learn to discriminate between novel and familiar
objects. Interestingly, whereas the hippocampus of CBP/
mice showed reduced acetylated H2B, but unchanged
H2A, H3, and H4 acetylation, p3001 forebrains, including
the hippocampus, had a reduction in H3 acetylation
(other histones were not examined). This difference
might originate in varying substrate specificities of CBP
and p300, but until all histone acetylation modifications
have been fully examined, this remains speculative.
Further evidence that histone acetylation is critical
for object memories was provided by the finding that the
HDACi SB ameliorates long-term object memory reten-
tion with no effect on short-term memory (321). A more
direct support for histone acetylation in object memory
comes from a recent study that addressed PP1-dependent
histone PTMs at the CREB promoter 1 day after NOR
training. At this timepoint, the CREB promoter was hy-
peracetylated at H3K14, concurrent with increased H3S10
phosphorylation and H3K36 trimethylation, which corre-
lated with increased CREB expression levels (171). Inter-
estingly, these PTMs were potentiated in mice in which
neuronal nuclear PP1 was inhibited, and which showed
enhanced object memory. A similar observation was
made upon estrogen treatment, which has been known to
ameliorate object memory (87), and which has now been
shown to concomitantly increase H3, but not H4 acetyla-
tion levels in the dorsal hippocampus of mice undergoing
an object memory task (370).
These findings are indicative of a marked correlation
between the strength of a memory and the amount to
which epigenetic modifications are present. In the future,
it will be interesting to determine whether naturally fast
learners can further increase their memory capacity by
the use of epigenetic drugs such as HDACis.
5. Other types of memory
Generally speaking, memory formation is amelio-
rated by experience-dependent plasticity of the nervous
system (327). Interactions with the environment such as
environmental enrichment (EE) provide a means for such
plasticity, and several histone PTMs have been found to
be upregulated following EE in the mouse forebrain (92).
In both the hippocampus and the cortex, several loci on
H3 and H4 showed increased acetylation, and, exclusively
in the cortex, H3K4 methylation was increased. These
results point to an overall relaxation of the chromatin
structure following EE, presumably responding to new
experiences with enhanced rates of gene transcription.
In addition to EE-induced plasticity, visual cortical
plasticity, i.e., the period during which ocular dominance
is established, represents another form of experience-
dependent plasticity. Ocular dominance refers to one eye
being associated with visual inputs from a particular re-
ceptive field, which is physiologically represented by neu-
rons in the visual cortex being connected to only that eye,
and not the other. In rodents, ocular dominance is fully
established several weeks after birth (see Ref. 327). Inter-
estingly, visual stimulation led to ERK/MAPK-dependent
H3 phosphoacetylation (i.e., H3S10 phosphorylation plus
H3K14 acetylation) changes in young animals (4 wk old),
but not in older ones (12 wk old) (276). Remarkably, upon
administration of the HDAC TSA in adults, plasticity was
reestablished, suggesting that histone PTMs are molecu-
lar mechanisms underlying visual cortical plasticity.
Furthermore, epigenetic mechanisms underlying memory
formation are not only restricted to rodents, but have
recently also been demonstrated in an arthropod, the crab
Chasmagnathus granulatus (85). Here, intensive contex-
tual learning resulted in increased H3 acetylation,
whereas weak learning did not. Accordingly, administra-
tion of the HDACis SB and TSA allowed the animals to
remember the context also after weak training.
From the examples presented above, it is becoming
obvious that evidence for epigenetic regulation of mem-
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ory formation is rapidly accumulating, not only for his-
tone PTMs, but also for DNA methylation. It is therefore
important to extend the notion of a histone code for
memory formation (189) to that of an epigenetic code
(113) for memory formation. Indeed, it is tempting to
consider such codes on the chromatin as “mnemonic”
marks, which would enable the brain to store and retrieve
stored pieces of information. To determine whether or
not this will turn out to be the case, epigenetic codes will
have to be investigated more thoroughly. The types of
questions that should be addressed, as well as techniques
available to do so, will be discussed in the last section of
this review.
D. Neuroprotection
The proper functioning of the nervous system re-
quires the integrity of all of its components, which need to
be maintained and protected against both extra- and in-
tracellular noxious signaling cascades. In the case of neu-
rons, an additional level of cellular integrity needs to be
preserved. As neurons are nondividing cells, the cell cycle
machinery must be permanently suppressed. In recent
years, epigenetic mechanisms, in particular the histone
acetylation machinery, have been found to play an inte-
gral part in the following crucial aspects of neuroprotec-
tion and neuronal maintenance. Paradoxically, epigenetic
research to date has provided strong evidence for both
HDACs and HDACis as being neuroprotective.
1. Neuroprotection against apoptosis
Adult neurons need to survive for the lifetime of an
organism and must be protected against programmed cell
death (apoptosis). This can be achieved by activating
neurotrophic pathways, or, more commonly, by silencing
proapoptotic pathways within the cell (21). In regards to
the former mechanism, the HDACi VPA has been found to
not only activate the expression of BDNF in neurons (98),
but also of glial cell line-derived neurotrophic factor
(GDNF) in astrocytes, and of HDAC1 gene expression
(42). For the latter, VPA has, on the one hand, been shown
to increase the expression of anti-apoptotic genes such as
B-cell lymphomia/leukemia 2 (Bcl2) (47, 316) and heat-
shock protein 70 (HSP70) (316), and, on the other hand,
to decrease the expression of genes with pro-apoptotic
properties such as interleukin-6 (IL-6) (316). This last
finding was recently confirmed by showing that TSA and
SB-mediated HDAC inhibition leads to the decreased ac-
tivity of caspase 3, another gene with pro-apoptotic prop-
erties (137). How VPA treatment results in such bidirec-
tional gene expression changes is unknown. However,
VPA administration was associated with increased H3
acetylation levels (316); therefore, the elevated expres-
sion levels of the anti-apoptotic genes seem likely to be a
direct effect of this treatment.
At least two HDACs are implicated in maintaining
low expression levels of pro-apoptotic genes in neurons.
HDAC1, in conjunction with histone deacetylase related
protein (HDRP), has been shown to deacetylate the pro-
moter region of c-Jun and thereby to inactivate its expres-
sion (243). Likewise, HDAC1 has been demonstrated to be
recruited by E2F4, a member of the E2F family of tran-
scriptional regulators, to the promoter region of the pro-
apoptotic gene B-myb, which was transcriptionally si-
lenced upon being deacetylated (200). Of note, the chro-
matin condensing effect of histone deacetylation is
supported by the HMT Suv39H1, which forms a complex
with HDAC1 at E2F4 to methylate B-myb promoter his-
tones at K9 (200).
HDAC3 has also been identified in the context of
neuronal antiapoptotic processes. Like HDAC1, HDAC3
binds to another member of the E2F family, E2F1 (263).
Upon caspase-mediated apoptosis, HDAC3 protein levels
are reduced, which might in turn lead to deregulated E2F1
transcription and further promotion of apoptosis, al-
though this has not been specifically tested.
2. Maintenance of neuronal identity
For neurons to maintain their identity, not only do
neuron-specific genes need be active, but cell-cycle genes
must be silenced. Two HDACs have recently been shown
to prevent cell cycle progression. The activity of the first,
HDAC1, was found to be downregulated in the CK-p25
mouse model of neurodegeneration (69), which led to a
reduced binding of HDAC1 to the chromatin, and an
upregulation of cell-cycling genes (159). Correspond-
ingly, virus-mediated overexpression of HDAC1, but not
HDAC2, not only blocked cell-cycle reentry, but also pro-
tected against caspase-mediated apoptosis and DNA dam-
age. Similarly, a class IIa HDAC, HDAC4, was shown to
inhibit the progression of HEK293T cells through the cell
cycle (214). Again, this effect was accompanied by sub-
stantial neuroprotection, in neuronal culture, against K-
mediated apoptosis and oxidative stress. Remarkably,
whereas the neuroprotective effect of HDAC1 could be
specifically attributed to its catalytic domain (159),
HDAC4 was still neuroprotective even without its cata-
lytic domain (214). This finding could be indicative of an
acetylation-independent effect of HDAC4 in neuronal
maintenance and protection, but further studies are
needed to clarify this point.
Both HDACs and HDACis thus seem to confer neu-
ronal identity as well as protection against intracellular
apoptotic pathways. This apparent discrepancy is likely
due to gene-specific modes of action by both epigenetic
modulators, and further studies investigating these effects
on a genome-wide scale are highly warranted.
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3. Neuroprotection against noxious extracellular
signals
HDACis have been demonstrated to be neuroprotec-
tive against various noxious extracellular signals such as
excitotoxicity, ischemia, hemorrhage, and inflammation.
Excitotoxicity is defined as the process by which neurons
are damaged in response to extracellular, glutamate-me-
diated overactivation, which results in pathologically high
levels of intracellular Ca2. Neuronal excitotoxicity can
be efficiently blocked by administration of VPA (80, 185,
186, 218), as well as TSA, SB (185, 186), and phenylbu-
tyrate (186). Although the molecular mechanisms have
not been fully investigated in all cases, they seem to
involve the upregulation of genes with neuroprotective
properties such as HSP70 (218) or -synuclein (185). TSA
and SB have also proven efficient against two models of
ischemic cell death: oxygen-glucose deprivation in pri-
mary cortical neurons (231) and middle cerebral artery
occlusion in rats (178). These effects were mediated by
the actin-binding proteins gelsolin and p21, respectively,
as no neuroprotection was observed in neurons lacking
these proteins. Although pathologically the opposite of
ischemic conditions, intracerebral hemorrhage (ICH) and
the resulting neuronal damage could also be attenuated
by administration of an HDAC. Thus VPA administration
after ICH induction led to the transcriptional upregulation
of HSP70, and concomitantly to the transcriptional down-
regulation of the proapoptotic gene Il6 (316). Finally,
VPA, TSA, and SB have also been shown to bestow neu-
ronal protection against inflammation. Surprisingly, how-
ever, this occurred not via the prevention of apoptotic
pathways, but via their induction in microglia (48). Thus,
upon HDACi treatment of primary neuron/glia cultures,
microglia underwent apoptosis, which subsequently pro-
tected the adjacent neurons from microglia-induced in-
flammation. Seemingly, therefore, HDACis differ in their
mode of action in different cell types in the CNS, which
might be caused by the differential expression of HDACs
in the brain (36) and their different sensitivity to HDACis.
Apart from the above-mentioned examples, several
HDACis have been attributed neuroprotective or other
beneficial effects in the context of neurodevelopmental,
neuropsychiatric, and neurodegenerative disorders. In the
following sections, we will cover the implication of epi-
genetic mechanisms in these disorders and summarize the
potential of HDACis as pharmacological treatments
against these disorders where applicable.
IV. PATHOLOGICAL EPIGENETIC REGULATION
I: DEVELOPMENTAL DISORDERS
Considering the pervasive nature of epigenetic regula-
tion across the many facets of CNS development and func-
tion, it is not surprising that the deregulation of epigenetic
regulation has been implicated in a number of neurodevel-
opmental disorders (Table 3). Fortunately, these drugs tar-
geting epigenetic modifications have demonstrated thera-
peutic potential in animal models for many of these.
Mutations in genes involved in epigenetic regulation
have been identified in disorders in which CNS develop-
ment proceeds abnormally, resulting in defects ranging
from subtle changes in synapse formation to gross abnor-
malities in brain formation. Collectively, these disorders
have provided direct evidence for the crucial role of epi-
genetic regulation in brain development, and have formed
the foundations for developing relevant animal models
and therapeutic strategies. It should be noted that some of
the mechanisms that are deregulated in the disorders
listed below are not limited to a developmental role. For
example, the HAT CBP, which is disrupted in Rubinstein-
Taybi syndrome, appears also to be necessary for normal
learning and memory in the adult. The diseases listed
below, however, are manifested during the period of brain
development and synapse maturation, and thus can be
classified as developmental disorders.
A. Rubinstein-Taybi Syndrome
A considerable number of neurodevelopmental dis-
orders have been shown to involve abnormal histone
acetylation. This is well-exemplified in Rubinstein-Taybi
syndrome (RTS), a rare congenital disorder (1:100,000–
125,000 prevalence in the United States) that is character-
ized by varying degrees of mental retardation, craniofacial
and skeletal abnormalities, as well as increased risk of
cancer (272). In the brain of affected people, RTS mani-
fests gross abnormalities such as abnormal cortical in-
folding and decreased white matter, as well as regional
hypoplasia (18, 306). Most RTS patients have mutations
that are mapped to the gene coding for the HAT CBP, and
many of these mutations have been shown to result in a
loss of HAT activity.
Critical insights into this disease have been gained
from transgenic animal models. Several mouse models for
RTS have been generated, including a straight CBP knock-
out displaying skeletal abnormalities and embryonic le-
thality. A heterozygous truncated CBP mouse displays a
phenotype that is more severe than the heterozygous null
mutant, suggesting a dominant-negative effect that may
compromise faithful recapitulation of RTS (6, 32, 170, 258,
365). Mice heterozygous for a truncated mutant CBP al-
lele, while displaying a more severe skeletal abnormality
phenotype than the heterozygous null mice display the
same defects in long-term memory with normal short-
term memory capacity (32, 258, 365). It appears, however,
that mice heterozygous for the CBP null allele may pro-
vide the most accurate model for RTS. These animals
display pathogenic features including growth retardation,
620 GRA¨FF, KIM, DOBBIN, AND TSAI
Physiol Rev • VOL 91 • APRIL 2011 • www.prv.org
skeletal abnormalities, and reduced long-term spatial
memory (170). Interestingly, CBP/ mice have a normal
short-term memory capacity, but defective long-term
memory as tested by contextual and cued fear condition-
ing, and object recognition tests (6). Long-term spatial
memory, however, as tested by the Morris water maze,
was intact, which may indicate that only specific subsets
of neural circuits that underlie learning and memory are
epigenetically deregulated in RTS.
When synaptic plasticity was examined at the elec-
trophysiological level in CBP/ mice, early-phase short
term LTP (E-LTP) was not impaired, but long-term (or
late) LTP (L-LTP) was significantly impaired, which cor-
relates with the observed behavioral abnormalities (170,
365). At a molecular level, reduced acetylation of histone
H2B was observed (6). These findings suggest that mental
retardation in RTS may involve defects in synaptic plas-
ticity too. However, an important question remaining is
what are the specific cellular processes that are disrupted
to cause defects in synaptic plasticity and learning and
memory. A large body of evidence demonstrating acute
roles for CBP in a variety of neuronal processes such as
axon outgrowth or neuronal survival suggest that multiple
factors may be in play in RTS (105, 255).
While pretreatment with the general HDAC inhibitor
SAHA did not alter basal synaptic transmission in CBP/
mice, it increased histone 2B (H2B) acetylation and ame-
liorated the reduced long-term LTP in these mice to near
wild-type levels. Furthermore, both SAHA and TSA treat-
ment resulted in a rescue of long-term memory, as mea-
TABLE 3. Epigenetic mechanisms in neurodevelopmental disorders
Disorder Epigenetic Modification Mechanism Organism Brain Area Reference Nos.
Rubinstein-Taybi
Syndrome
Histone acetylation + Reduced global HAT activity
due to loss-of-function in
CBP
Mouse Hippocampus 6, 170, 258, 365
Rett syndrome DNA methylation + MeCP2 mutations lead to
reduced functioning of
MeCP2, which normally
recognizes methylated
CpG islands and acts as a
transcriptional repressor
Human lymphocytes
Mouse
NA
Hippocampus,
cortex, cerebellum
8
49, 61, 127
DNA methylation +,
histone acetylation
*, histone
methylation *+
MeCP2 mutations cause
aberrant transcriptionally
permissive histone
acetylation and
methylation marks
Mouse and murine cell
culture
Cortex, cerebellum 220, 307
Fragile X DNA methylation * Nucleotide expansions
within FMR1 and -2
results in CpG island
hypermethylation
Human and mouse cell
culture
NA 11, 55, 56
DNA methylation *,
histone acetylation
+ histone
methylation *+
5-Aza treatment of FXS cell
lines not only alters DNA
methylation but also
histone acetylation and
methylation
Human patient-derived
cell lines
NA 330, 331
Schizophrenia DNA methylation * GAD67 and SOX10 promoter
regions are
hypermethylated
correlating with reduced
mRNA levels
Human post mortem
brain
Cortex 124, 136, 146, 349
DNA methylation + COMT promoter is
hypomethylated
correlating with increased
mRNA levels
Human post mortem
brain
Frontal lobe 1
ATRXS DNA methylation *+ Mutations in ATRX result in
aberrant DNA methylation
patterns
Human patient-derived
cell lines
NA 109, 110
ATRX forms a silencing
complex with MeCP2 that
is disturbed in ATRXS
Mouse Forebrain 157
Coffin-Lowry
syndrome
Histone
phosphorylation?
Substrates for RPS6KA3,
mutated in Coffin-Lowry,
include histones
Human patient-derived
cell lines
NA 233, 319
ATRX, X-linked -thalassemia/mental retardation; ATRXS, X-linked -thalassemia/mental retardation syndrome; COMT, catechol-O-methyl
transferase; CBP, CREB-binding protein; FMR1, fragile X mental retardation 1; GAD67, glutamic acid decarboxylase 67; HAT, histone acetyltrans-
ferase; MeCP2, methyl CpG binding protein 2; NA, not applicable; PTM, posttranslational modification; RPS6KA3, ribosomal protein S6 kinase, 90
kDa, polypeptide 3; SOX10, SRY-related HMG-box 10.
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sured by cued and contextual fear conditioning to levels
similar to controls (6, 170). These results establish RTS as
a disorder of defective histone acetylation, and provide
evidence that HDAC inhibitors may be useful as a thera-
peutic strategy against disorders involving defective his-
tone acetylation.
B. Rett Syndrome
Rett Syndrome (RTT) is a relatively common CNS
developmental disorder, which is manifest almost exclu-
sively in females by virtue of it being transmitted as an
X-linked dominant trait and thus being lethal in males
(221). RTT has a prevalence of 1 in 10,000 females in the
United States. RTT can be classified as a progressive
developmental disorder, as cases follow a period of nor-
mal development up to 18 mo, followed by regression in
motor and language skills and deceleration of head
growth. This regression results in mental retardation and
autistic features; thus RTT is also considered an autism
spectrum disorder. At the anatomical level, significant
reductions in both gray and white matter are observed at
the regressive stage (249). At the cellular level, neurons in
RTT patients may have a reduced density of dendritic
spines (180), and murine RTT models display axonal and
dendritic spine abnormalities (20). Moreover, mouse
models of RTT exhibit an overall decrease in exploratory
activity (49, 127), show severe cognitive deficits, and have
impaired synaptic plasticity (61).
The underlying defect in80% of RTT cases has been
mapped to mutations in the MeCP2 gene, which impair
MeCP2 function (8). Importantly, the cognitive deficits
observed in RTT mouse models can be reversed by over-
expression of wild-type human MeCP2 protein in young
(10-wk-old) animals (61). Intriguingly, however, in 20-wk-
old mice, human MeCP2 overexpression induces seizures,
suggesting that an overdose of MeCP2 can have deleteri-
ous effects, presumably by silencing genes that, under
physiological conditions, are active and required for a
proper brain functioning.
One identified target of MeCP2 is the Bdnf gene.
MeCP2 mutant mice have reduced BDNF levels. This
reduction, and the neuronal atrophy characteristic of
RTT, can be reversed by forebrain-specific overexpres-
sion of Bdnf in vivo (46), an effect that was recently
confirmed in cultured hippocampal neurons (180). In ad-
dition to Bdnf, a recent study identified seven other genes
as direct binding targets of MeCP2 in the mouse brain
(346), including myelin-associated proteins and dopamine
decarboxylase. Yet more genes are likely to be discov-
ered, as MeCP2 has been associated with dendritic
growth and spine maturation (371), which is thought to
occur through the derepression of target genes involved
in development processes (44, 318).
In addition to regulating DNA methylation, MeCP2
also influences histone PTMs, particularly histone acety-
lation and methylation. At the promoter region of Bdnf,
this is mediated by the formation of a complex between
MeCP2 and HDAC1 (220), which reduces the acetylation
of both histone H3 and H4. This effect is accompanied by
the increased dimethylation of H3K9 and the decreased
dimethylation of H3K4, two posttranslational histone
modifications that inhibit and promote gene transcription,
respectively (172). This suggests a cooperative contribu-
tion of epigenetic modifications for gene silencing and is
consistent with the observation that mice with deficient
MeCP2 have hyperacetylated H3 (307). Accordingly, a
recent study found that infusion of the HDACi SAHA in
the mouse amygdala produces behavioral deficits remi-
niscent of RTT (3).
These results strongly argue for an overall increase in
gene transcription in RTT, due to loss of MeCP2-mediated
gene silencing, possibly in conjunction with aberrant his-
tone PTMs. However, in light of the recent observation
that MeCP2 also fulfills other roles, such as transcrip-
tional activation and mRNA splicing (44), these func-
tions cannot be ruled out as mechanisms underlying RTT
pathology.
C. Fragile X Syndrome
Fragile X Syndrome (FXS) is the most common in-
herited form of mental impairment, with a prevalence of
1:4,000 to 1:8,000 in the United States (102). FXS mani-
fests as a spectrum of abnormalities, mostly CNS related,
which range from mild to severe. These include mental
retardation, autism, and mild skeletal and muscular ab-
normalities. The cause of FXS has been identified as 200
or more copies of CGG and CCG trinucleotide expansions
at the 5= end of the fragile X mental retardation gene
(FMR1) and, in rare instances, a second gene, FMR2 (11,
107, 120). These expansions result in extensive CpG meth-
ylation, which in turn leads to the silencing of the entire
genetic region, and a constriction of the chromosome
band Xq27.3, giving the “fragile” appearance from which
the syndrome derives its name. FXS brains appear grossly
normal, but a key feature of FXS is that certain areas of
the brain display abnormally long and thin dendritic
spines, reminiscent of immature spines, at an abnormally
high density (102). Thus, within the brain, the predomi-
nant defect appears to be that of spine maturation.
Importantly, treatment of lymphoblastoid cell from
FXS patients with 5-aza reversed FMR1 promoter hyper-
methylation and restored FMR1 mRNA and protein ex-
pression to control levels (56). When 5-aza was combined
with the HDACis 4-phenylbutyrate, SB, and TSA, FMR1
expression is further potentiated (55), suggesting a joint
deregulation of histone acetylation and DNA methylation
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as causative mechanisms of FXS. Two other studies fur-
ther demonstrated an implication of histone methylation
in FXS. Gene-silencing H3K9 methylation was decreased
with 5-aza treatment, which simultaneously increased
gene-activating H3K4 methylation, together with an in-
crease in FMR1 gene expression (330, 331). It should be
noted, however, that these findings are based on only a
few case studies, and therefore require further confirma-
tion.
In conclusion, FXS is an example of a rare congenital
disorder that does not involve mutations in the coding
sequence of a gene, but instead a mutation (expansion) in
a noncoding sequence that results in the abnormal recruit-
ment of several epigenetic markers. This, in turn, leads to
an epigenetic repression of a gene pivotal for synapse
development.
D. Other Developmental Disorders
1. X-linked alpha thalassemia mental retardation
syndrome
X-linked alpha thalassemia mental retardation syn-
drome (ATRXS) is an extremely rare and poorly under-
stood X-linked disorder (168 reported cases as of 2006),
which is only manifest in males, with normal female
carriers (109). ATRXS is characterized by mental retarda-
tion, occasional autistic-like behavior, alpha thalassemia
(a form of anemia), and other abnormalities. ATRXS is
caused by mutations in the alpha thalassemia/mental re-
tardation syndrome X-linked homolog (ATRX) gene, a
member of the helicase/ATPase family proteins, which
regulate various processes of nucleosome remodeling,
DNA repair, and chromosome segregation. A recent re-
port found that ATRX functionally interacts with MeCP2
and cohesin to form a silencing complex that was shown
to repress an imprinted locus, H19 under physiological
conditions, but which in ATRXS becomes pathologically
expressed (157). Furthermore, ATRXS patients display
changes in the methylation of highly repetitive DNA se-
quences in heterochromatin regions (110), which pro-
vides further evidence for the involvement of epigenetic
mechanisms in ATRXS.
2. Coffin-Lowry Syndrome
Some congenital syndromes featuring defective CNS
development may also involve epigenetic mechanisms in
their etiology, although definite links have not been es-
tablished. For example, Coffin-Lowry Syndrome (CLS) is
a rare (estimated 1 in 40,000–100,000) X-linked condition
with severe mental retardation in males and varying de-
grees of cognitive defects in females; additional symp-
toms include delayed postnatal growth as well as cardio-
vascular and skeletal defects (219). This disorder is
caused by mutations in RPS6KA3, a ribosomal protein S6
kinase family member that is involved in the MAPK sig-
naling pathway, and for which multiple substrates have
been identified (233). As targets of ribosomal protein S6
kinase family members include histones, it is plausible
that CLS may involve a deregulation of histone homeo-
stasis triggered by dysfunctional RPS6KA3. Yet, alterna-
tive roles of mutated RPS6KA3 on other targets genes
cannot be ruled out.
3. The case of imprinted genes
Imprinted genes, i.e., genes that, via epigenetic mech-
anisms (281), are either exclusively maternally or pater-
nally expressed, represent a class of genes with both a
physiological function and an inherent pathological po-
tential, as the beneficial effects of diploidy are in effect
overturned (364). The epigenetic imprint of these genes is
established during embryonic development, and although
imprinting has been detected in a wide variety of somatic
tissues, an intriguingly high percentage of these genes is
also expressed in the brain. As a matter of fact, over 1,300
loci or more than 300 gene show parent-of-origin patterns
in gene expression in the brain (117, 118), and many of
these patterns vary from one brain region to the other,
leading to the question of whether imprinted genes have a
specific function in the brain.
Here, precise evidence is still scarce, but there seems
to be an overall trend of expression patterns of imprinted
genes that is in accordance with the “intragenomic con-
flict” theory of imprinting (240). This theory stipulates
that it is in the interest of the mother, and thus of mater-
nally expressed genes, to distribute resources between
offspring and between mother and infant fairly, whereas it
is in the interest of the father and thus paternally ex-
pressed genes to maximize resources. This is exemplified
by the textbook example of imprinted genes, paternally
expressed insulin-like growth factor 2 (Igf2) and mater-
nally expressed insulin-like growth factor receptor 2
(Igf2r) that are also expressed in the brain (118). Other
examples include paternally expressed gene 3 (Peg3),
which is involved in oxytocin production, or maternally
expressed ubiquitin protein ligase 3a (Ube3a), which in-
teracts with the receptors for the sex hormones proges-
terone and androgen (reviewed in Ref. 364).
Two recent studies have now started to shed light
onto how an epigenetic deregulation of genomic imprints
can lead to behavioral deficits. The first one assessed the
functions of the transcription factor YY1 by RNAi (164).
Knockdown of YYI drastically upregulated Peg3 in the
neonatal mouse brain by changing the methylation profile
in its promoter region, which concomitantly also reduced
the birth weight of the pups. The second investigated the
role of the zinc-finger protein Krüppel-associated box
(KRAB)-associated protein 1 (KAP1) by lentivirus-medi-
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ated forebrain-specific knockdown (148). Mice deleted for
KAP1 showed increased anxiety-like behaviors and cog-
nitive impairments, which was accompanied by abnor-
mally high expression levels of normally silenced im-
printed genes, including Mkrn3, which, like Ube3a, is a
ubiquitin ligase. Focusing on PTMs of histones, the pro-
moter region of Mkrn3 was found to be hyperacetylated
on H3 and H4 compared with control brains, and hypom-
ethylated on H3K9, which are all three marks of transcrip-
tionally active genes. These two studies clearly show the
inherent pathological potential of imprinted genes in the
brain. With the advances of the techniques at our hands to
more thoroughly investigate epigenetic mechanisms,
more such examples of deregulated imprinted genes in
the brain are likely to surface. This in turn will eventually
lead to the deciphering of their physiological function.
V. PATHOLOGICAL EPIGENETIC REGULATION
II: PSYCHIATRIC DISORDERS
Neuropsychiatric disorders are mental disorders that
can change a personality entirely. Addictive-like behav-
iors, depression, anxiety-related disorders, and abnormal
stress vulnerability all fall into that category. The often
long-lasting and repeatedly occurring nature of these be-
haviors designate lasting gene expression changes and an
epigenetic regulation thereof as key underlying molecular
candidates (Table 4).
A. Addiction
Drugs with psychoactive properties can be broadly
divided into psychostimulants such as cocaine and am-
phetamine, sedatives such as benzodiazepines and alco-
hol, and analgesic opiates such as opium and morphine.
They profoundly influence human (and animal) behavior
by increasing or decreasing the brain’s excitability or by
manipulating the brain’s reward pathway, including the
dopaminergic neurons connecting the ventral tegmental
area (VTA) to the nucleus accumbens (NAc). Often, re-
petitive exposure to such drugs can lead to the brain
“asking for” increasing amounts of that drug, which ulti-
mately can lead to substance dependence, i.e., addiction.
A substantial body of evidence suggests that epigenetic
mechanisms underlie addictive-like behaviors for all three
types of psychoactive drugs.
1. Addiction to psychostimulants
A) COCAINE. Cocaine exposure can either occur acutely
and chronically, whereby the latter is often reached by
self-administration (also in animal models). Acutely a sin-
gle injection of cocaine was found to increase overall H4
acetylation in the promoter region of the immediate early
gene c-fos, and of the transcription factor FosB in the rat
striatum (175). Additionally, for c-fos, but not FosB, the
promoter region was phosphoacetylated at H3. These
findings were replicated for at least the H4 acetylation (on
K5) and H3 phosphorylation (on S10) independently by
another study (33). Mechanistically, the acetylation
changes seem to be mediated by the HAT CBP, which
bound to the promoter of FosB upon acute cocaine ad-
ministration (191), whereas the phosphorylation changes
seem to be caused by the protein kinase MSK1, since
MSK1 knockout mice did not display H3 phosphorylation
following acute cocaine administration (33).
Similar to acute cocaine exposure, repeated injec-
tions of cocaine were found to increase phosphoacetyla-
tion in the mouse striatum, and drug-seeking behavior
could be further amplified by the HDACi SB (298). In
more gene-specific studies, chronic cocaine exposure led
to hyperacetylated H3 in the rat striatum in the promoter
region of FosB, as well as of Bdnf and Cdk5 (175), two
genes implicated in chronic cocaine exposure (24, 119).
The expression of c-fos, however, was not changed, con-
sistent with its promoter region not undergoing H3 hyper-
acetylation (175). Similar to FosB and Bdnf, H3 hyper-
acetylation was also observed in the promoter region of
calmodulin kinase II  (CamKII) in the rat NAc follow-
ing chronic cocaine exposure (353). Accordingly, in both
studies, the HDACi SB increased the cocaine dependency
as indicated by more craving-like behaviors, and virus-
mediated overexpression of the class IIa HDAC, HDAC4
into the corresponding brain areas abolished such behav-
ior (175, 353). Interestingly, virus-mediated overexpres-
sion of HDAC5, another class IIa HDAC into the striatum,
reduced drug-seeking behaviors in a similar way. How-
ever, no such reduction could be detected when a third
class IIa enzyme, HDAC9, was overexpressed (285).
These findings could be due to differential tissue distri-
bution of class IIa HDACs (36), or of a preferential acti-
vation of HDAC4 and -5 upon cocaine exposure, but more
refined studies are needed to clarify this point.
To verify if chronic cocaine administration is globally
characterized by transcription-facilitating hyperacetyla-
tion changes, a recent study compared the expression
profiles and the epigenetic promoter regulation of genes
induced upon chronic cocaine administration on a ge-
nome-wide scale (284). This study found that overall H3
acetylation and methylation levels were, as a matter of
fact, bidirectionally changed. This was accompanied by
an equally frequent binding of the transcription factor
FosB to gene-activating hyperacetylated H3 and H4 lev-
els as to gene-silencing hypermethylated H3K9/K27 levels,
highlighting its cross-talk with epigenetic marks and con-
firming its dual effect on gene transcription (226). An-
other interesting finding of this study was that chronic,
but not acute, cocaine administration significantly en-
hanced the expression of the class III HDACs, the sirtuins,
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in particular SIRT1 and SIRT2. Their inhibition via sirti-
nol and their activation via resveratrol decreased and
enhanced the spine number in the NAc, respectively, sug-
gesting a critical role for sirtuins in mediating plasticity
changes following addiction.
A recent study has now identified the first HMT re-
sponsible for the altered histone methylation upon
chronic cocaine administration. Thus chronic cocaine ad-
ministration not only led to reduced dimethyl H3K9 levels,
but concomitantly diminished the expression of the
H3K9-specific HMT G9a, and not of other HTMs, in the
NAc (224). With the use of double transgenic mice induc-
ibly overexpressing FosB, the downregulation of G9a
was found to be mediated by FosB, substantiating the
predominant role of this transcription factor in cocaine
addiction.
TABLE 4. Epigenetic mechanisms in psychiatric disorders
Context Epigenetic Modification Mechanism Organism Brain Area Reference Nos.
Addiction to cocaine Histone acetylation * Acute and chronic cocaine
exposure induce
differential H3 and H4
acetylation, in part
mediated by CBP
Mouse and rat Striatum and
nucleus
accumbens
33, 175, 191, 284,
298, 353
Histone phosphoacetylation * Acute cocaine exposure
leads to H3
phosphoacetylation
changes with MSK1
mediating the
phosphorylation
Mouse Striatum and
nucleus
accumbens
33, 175
Histone methylation + Chronic cocaine exposure
reduces H3K9
dimethylation, mediated
by the HMT G9a
Mouse Nucleus accumbens 224, 284
DNA methylation * Chronic cocaine exposure
increases MeCP2 and
MBD1 expression
Rat Striatum, cortex,
hippocampus
41, 144
Chronic cocaine exposure
increases Dnmt3a
Mouse and rat Nucleus accumbens 179
to amphetamine Histone acetylation +
and methylation *
Chronic amphetamine
exposure reduces
histone acetylation and
increases H3K9
dimethylation on c-fos
Mouse Striatum 283
DNA methylation * Mice hypomorphic for
MeCP2 show reduced
amphetamine-induced
place preference
Mouse Nucleus accumbens 74
to alcohol Histone acetylation * Acute and chronic alcohol
exposure increase H3
and H4 acetylation
Rat Amygdala, frontal
cortex, striatum
261, 267
to morphine Histone phosphorylation * HDACi SB facilitates
addictive behaviors to
morphine and increases
H3 phosphorylation (but
not acetylation
Mouse Striatum 298
Depression Histone acetylation + HDAC2 and HDAC5 are
downregulated upon
chronic social defeat
stress
Mouse,
humans
Nucleus accumbens 66, 285
Histone methylation * Repressive methyl marks
on H3 are upregulated
in the promoter region
of BDNF and orexin
after chronic social
defeat stress
Mouse Hippocampus,
hypothalamus
211, 340
DNA methylation * Increased DNA
methylation levels at
GABAA 1 and elevated
levels of DNMT3b are
seen in depression
Humans Prefrontal cortex 274
BDNF, brain-derived neurotrophic factor; CBP, CREB-binding protein; DNMT3b, DNA methyltransferase 3b; GABAA 1, -aminobutyric acid A
receptor 1; H, histone; HDAC, histone deacetylase 2; HDACi, HDAC inhibitor; K, lysine; MBD1, methyl-CpG binding protein 1; MSK1, mitogen- and
stress-activated kinase 1; SB, sodium butyrate.
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In addition to histone PTMs, several studies have
determined that DNA methylation and its enzymatic me-
diators also regulate cocaine addiction. Thus chronic co-
caine exposure led to increased expression levels of
Dnmt3a (but not of Dnmt1 or Dnmt3b) in the NAc, and
virus-mediated overexpression of this enzyme in control
animals abolished cocaine-induced place preference
(179). Morphologically, these behavioral effects were ac-
companied by increased spine density in the NAc. Of note,
the enhanced expression of Dnmt3a seems to be itself
caused, at least in part, by epigenetic modifications, since
the transcription-enabling trimethyl H3K4 mark was
found in its promoter region, but not in that of the other
enzymes examined. Similar to Dnmt3a, MBD1 and MeCP2
levels were increased following chronic cocaine self-ad-
ministration in the rat dorsal striatum, cortex, and hip-
pocampus (41, 144), and virus-mediated knock-down of
MeCP2 decreased cocaine intake (144). Interestingly,
MeCP2 regulates cocaine addiction via downregulating
microRNAs miR-212 and miR-132, which then allows for
increased expression levels of BDNF, a molecule known
to promote cocaine self-administration (114).
Focusing on the reversal of addiction, a recent study
revealed that also extinction of cocaine-induced behavior
can be facilitated by the HDACi SB, which was accompa-
nied by increased H3K14 acetylation levels in the mouse
NAc (215). This finding is thus somewhat in contrast to
other studies reporting that HDACis facilitate cocaine
addiction (175, 298, 353), but reminiscent of the fact that
VPA can facilitate extinction of fear memory (34). These
observations would therefore speak in favor of extinction
being a relearning of the nonconditioned state, be that
nonaddictive or non-fear-conditioned, rather than simple
erasure of the memory trace (247). The future challenge
lies here to determine what occurs molecularly by HDAC
inhibition that facilitates extinction.
Finally, it is interesting to note that at least for the
genes surveyed in these studies, acute and chronic co-
caine exposures seem to differ in the epigenetic program-
ming they activate (339), with acetylated H3 being a pref-
erential mark for the chronic type. This observation is
reminiscent of the differential epigenetic programming
elicited by acute and chronic seizures, in which chronic,
but not acute, ECS altered H3 acetylation (341). Hence,
H3 acetylation might represent an epigenetic mark pref-
erentially installed on continuously activated genes.
B) AMPHETAMINE. Similar to chronic cocaine exposure,
the expression of c-fos was found unchanged after
chronic amphetamine exposure (283), whereas the ex-
pression of FosB, a stable splice product of FosB was
transcriptionally increased (227). As it turns out, FosB is
the causative agent of c-fos silencing. Thus, after chronic
amphetamine exposure, FosB was found to bind to the
c-fos promoter region and to interact with HDAC1, which
was accompanied by decreased c-fos promoter acetyla-
tion (283). Indicative of a cross-talk between FosB,
HDAC1, and the HMT Suv39H1, the mRNA expression of
which was upregulated, dimethylation of H3K9 was in-
creased at the c-fos promoter, thus further substantiating
c-fos’ transcriptional silence in the context of amphet-
amine addiction.
Equally similar to cocaine addiction, a recent report
also demonstrated a role for DNA methylation in amphet-
amine addiction. Thus mice hypomorphic for MeCP2
showed reduced conditioned place preference, a measure
of addiction, to amphetamine, and phosphorylation of
MeCP2, a mark of the protein’s activation, was signifi-
cantly increased following amphetamine exposure in the
NAc (74).
2. Addiction to sedatives
A) ALCOHOL. Alcohol addiction is a chronic recurring
disorder that causes alterations in synaptic plasticity and
related neuronal functions in the brain (reviewed in Ref.
238). Although some evidence has already suggested a
contribution of epigenetic mechanisms to alcohol-medi-
ated addiction (see Ref. 113), most of these studies have
focused on peripheral tissue, but not the brain. Recently,
however, epigenetic alterations following both acute and
chronic alcohol consumption have also been shown to
occur in the brain.
The first such study found a striking correlation be-
tween the anxiolytic effects of acute alcohol consumption
and an increase in H3 and H4 acetylation in the rat
amygdala, which was accompanied by decreased HDAC
activity and increased protein levels of the HAT CBP
(261). Conversely, withdrawal from chronic alcohol con-
sumption led to the exact opposite molecular effects,
which, together with the anxiety-like behavior upon with-
drawal, could be reversed by TSA administration.
Chronic alcohol consumption was further shown to
not only affect amygdala epigenetics, but also cortical and
striatal mechanisms. Four- to five-week-old rats were
chronically administered ethanol for several consecutive
days, and their brains were analyzed 2 days later. Both the
frontal cortex and the NAc had hyperacetylated H3K14
and H4K12 levels, whereas no change was found in the
hippocampus (267). Interestingly, however, striatal acet-
ylation levels were decreased, and adult rats exposed to
the same dose of alcohol showed no epigenetic changes
in their brain. This suggests two things: 1) alcohol admin-
istration elicits brain-region specific histone codes, and 2)
there seems to be a critical period as to when alcohol
exposure can elicit brain-specific epigenetic changes.
However, more studies are still required to circumscribe
this time-window better. Alternatively, the amount of al-
cohol and whether or not it was administered in bulk or
repetitively might also result in different epigenetic out-
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comes. Indeed, in a rat model of “binge” drinking, no
epigenetic changes were found in the brain (165).
3. Addiction to analgesic opiates
A) MORPHINE. Morphine is one of the most common
analgesic opiates, which, when repetitively administered,
can lead to addiction. In the brain, morphine acts via
-opioid receptors (MORs), which are unevenly distrib-
uted throughout different brain areas. This distribution
pattern seems to be caused, at least in part, by brain-area
specific DNA methylation and histone PTMs (143). In the
cerebellum, for instance, the MOR promoter DNA is
highly methylated and bound by both DNMT1 and MeCP2,
which results in low MOR expression. In the hypothala-
mus, in contrast, the MOR is transcriptionally active,
which is associated with low DNA methylation patterns
and absent binding or DNMT1 and MeCP2. Accordingly,
in vitro, MOR expression could be induced by the dem-
ethylating drug 5-aza, and also by the HDACi TSA, suggest-
ing that histone acetylation coregulates MOR expression
(143). On the behavioral level, the HDACi SB facilitated
morphine-induced addictive behaviors and increased
phosphorylated H3S10 in a subpopulation of striatal neu-
rons in mice (298). However, the mechanisms underlying
these observations, and in particular whether the behav-
ioral changes are due to epigenetic alterations of the MOR
promoter remain to be elucidated.
B. Depression
Depression is a very common enduring mood state
characterized by despair, helplessness, and social with-
drawal. Often, antidepressant treatments can only change
this condition when given repeatedly and over a long
period, suggesting the involvement of stable molecular
changes (339). In animals, depression can be mimicked by
social defeat, a behavioral paradigm in which the exper-
imental subject is exposed to a more aggressive conspe-
cific (22). When brought together again, chronically ex-
posed animals tend to avoid contact with the aggressor
(339). On the level of the chromatin, such social avoid-
ance was shown to result in stable hippocampal down-
regulation of two splice variants of Bdnf, BdnfIII, and
BdnfIV, accompanied by increased transcriptionally re-
pressive H3K27 dimethylation of their promoter regions
(340). Strikingly, this histone modification was still pres-
ent several weeks after the removal of the aggressor,
indicating a persistent epigenetic mark of these two Bdnf
transcripts. Similarly, chronic social defeat stress was
recently found to increase the repressive mark H3K9 trim-
ethylation in the promoter region of orexin, a gene impli-
cated in emotional processes, in the murine hypothala-
mus (211).
Treatment of these mice with the antidepressant
imipramine reversed the repression of the Bdnf tran-
scripts, surprisingly, however, not through reversal of the
dimethylated H3K27, but via increased H3 acetylation (on
K9/K14) and H3K4 dimethylation (340), markers of tran-
scriptional activation (172). The upregulated H3K4 dim-
ethylation upon imipramine treatment was further cor-
roborated in an in vitro study using another class of
antidepressants, monoamine oxidase (MAO) inhibitors,
which resulted in the same H3K4 dimethylation increase
(184).
A potential explanation for at least the acetylation
changes is the downregulation of HDAC5 upon chronic
imipramine administration (340). Presumably, the meth-
ylation changes would then be caused by an HDAC5-
mediated epigenetic cross-talk. Accordingly, viral-medi-
ated overexpression of HDAC5 reversed the imipramine-
induced antidepressant increase in H3 acetylation and
BdnfIII and BdnfIV transcription (340). Based on these
grounds, HDACis came soon into the focus as potential
antidepressants (339), which was experimentally con-
firmed when SB was found to exert antidepressant effects
not only in the chronic social defeat model (340), but also
in mice undergoing a tail suspension test (302), a behav-
ioral paradigm to assess despair. However, it should be
noted that the HDACi SB failed to exert antidepressant-
like effects in the forced swim test (125), another test for
behavioral despair. Therefore, it is likely that different
types of HDACis are differently effective as antidepres-
sants by each modifying distinct cellular targets.
Notably, chronic social defeat was found to have the
opposite effect on HDAC5 in a different brain region, the
NAc (285). Here, chronic stress decreased the mRNA levels of
HDAC5, whereas imipramine treatment increased them.
Accordingly, HDAC5 knockout mice showed strong signs
of depression, which could not be ameliorated by imipra-
mine treatment. In agreement with these results, NAc
levels of another HDAC, HDAC2 (but not of HDAC1 or
HDAC3), were found to be significantly downregulated
after chronic social defeat in mice, and in human post
mortem NAc samples of persons with a history of clinical
depression (66). Given such downregulation of HDACs in
depression, it is therefore somewhat surprising that HDA-
Cis have been demonstrated to have antidepressant prop-
erties. This may be due to either other HDACs that have
not been monitored in these studies, to the brain-region
specific distribution of HDACs (36), or, although unlikely,
to HDAC-unrelated properties of HDACis. Notwithstand-
ing, providing further support for the efficacy of HDACis
against depression, in situ injections of MS-275, a class I
HDAC-specific inhibitor, reversed the depressive-like
phenotypes in mice after chronic social defeat (66).
This effect could be replicated by the HDACi SAHA and
was further accompanied by increased H3K14 acety-
lation (66).
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In addition to histone PTMs, there is evidence for an
impact of antidepressants on DNA methylation. Chronic
antidepressant treatment with fluoxetine not only in-
creased HDAC2 mRNA levels accompanied by hypoacety-
lated levels of H3 on K9 and K14, but it also enhanced
MeCP2 and MBD1 transcription in the rat forebrain, in-
cluding the frontal cortex, hippocampus, and striatum
(41). The antidepressant-dependent increase in MeCP2
was specific to GABAergic interneurons (41). This finding
is of particular interest, since abnormal GABAergic trans-
mission and abnormalities in GABA-related gene methyl-
ation have been linked to major depression and suicide.
Depressed patients who committed suicide have higher
levels of methylation in the GABAA 1-receptor subunit
promoter, and increased DNMT3b mRNA and protein in
the prefrontal cortex compared with control individuals
who died of other causes (274). This suggests the intrigu-
ing possibility that antidepressant treatments might spe-
cifically target the epigenetic machinery in cell types af-
fected by depression, but this remains speculation for the
time being.
C. Schizophrenia
Schizophrenia is a common form of psychosis, with
an approximate prevalence of 1–2% in the United States
among people 18 years old and older (280). Schizophrenia
is characterized by “positive” symptoms such as halluci-
nations and thought disorder as well as “negative” symp-
toms such as asociality, anhedonia, and an overall lack of
motivation. While the causes of schizophrenia are not
well understood, they are likely to involve a genetic pre-
disposition as well as environmental factors during the
pre- and postnatal development (reviewed in Ref. 84).
The molecular mechanisms underlying the influence
of such environmental factors upon the onset and pro-
gression of schizophrenia are not fully understood, but
several lines of evidence suggest that schizophrenia is
associated with aberrant epigenetic regulation in both
neurons and oligodendrocytes. Initial studies implicated
the extracellular matrix protein reelin, a glycoprotein that
is expressed in GABAergic neurons during development
and adulthood, and is important for neuronal migration
(64, 83). Post mortem analyses in schizophrenic patients
revealed that reelin mRNA and protein expression are
significantly reduced in several brain regions (123, 145).
This reduction may be caused by an alteration of the
methylation profile of the reelin promoter, possibly by
hypermethylation, since in vitro administration of the
DNMT inhibitor 5-aza increases reelin gene expres-
sion (50).
Glutamate decarboxylase (GAD67), which catalyzes
the production of GABA, provides an even better-docu-
mented example of the involvement of DNA hypermeth-
ylation in schizophrenic GABAergic dysfunction. GAD67
mRNA and protein expression are downregulated in cor-
tical structures of schizophrenic patients (123, 145). This
decrease is paralleled by increased methylation of the
GAD67 promoter (136) and, indicative of cross-talk be-
tween histone acetylation and DNA methylation, inversely
correlated to HDAC1 levels (308). Similar to the GABAergic
system, increased methylation of the CpG island of the
promoter region of the oligodendrocyte-specific tran-
scription factor SOX10 and the decreased mRNA expres-
sion of SOX10 were observed in the brains of schizo-
phrenic patients (146).
The abnormal hypermethylation of the GAD67 and
SOX10 promoters are hypothesized to be caused by ele-
vated levels of SAM and increased expression of DNMT1
(124, 349). Indeed, the administration of SAM can induce
psychotic episodes in some schizophrenic patients (10).
Due to the aberrant hypermethylation observed in the
schizophrenic brain, DNMT inhibitors have been pro-
posed as potential therapeutic agents for this disease (50,
63, 189).
Unlike the hypermethylation in the GABAergic sys-
tem observed in schizophrenic patients, hypomethylation
was detected in the dopaminergic system. Increased ac-
tivation of catechol-O-methyltransferase (COMT), an en-
zyme involved in the degradation of dopaminergic neu-
rotransmitters, is associated with impaired attention and
working memory, and with an elevated risk for schizo-
phrenia (347). Reduced methylation of the COMT pro-
moter has been observed in the frontal lobe of schizo-
phrenic patients and is associated with increased activa-
tion of the gene (1).
The chromatin in the brains of schizophrenic patients
is also characterized by differential histone PTMs. For
instance, VPA, a potent HDACi, is regularly prescribed as
a mood stabilizer in the treatment of schizophrenia (112).
Notably, VPA administration not only decreases HDAC
activity, but also increases reelin expression both in vitro
and in vivo by decreasing reelin promoter methylation
(50, 338). While the mechanism explaining the relation-
ship between HDAC inhibition and altered DNA methyl-
ation is still unknown, HDAC inhibition is thought to
operate via regulating the accessibility of DNMTs to pro-
moter regions, or by direct induction of DNA demethylase
activity (176, 339). Additionally, two antipsychotic drugs
that act as dopamine D2 receptor antagonists, haloperidol
and raclopride, induce phosphoacetylation of H3 in the
mouse striatum (194). Thus it appears that decreased
acetylation is also involved in the pathology of schizo-
phrenia, which, in conjunction with aberrant DNA hyper-
methylation, can be readily reversed by HDACis. How-
ever, due to the nonspecific effects of the antipsychotics
described above, direct evidence for this hypothesis is
lacking.
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D. Vulnerability to Stress
Heightened stress vulnerability and inappropriate
stress-coping behaviors are common brain dysfunctions.
It is now widely recognized that an organism’s stress
resistance is predetermined by the early life environment,
both before and after birth (210, 304). The environments
experienced during these periods, i.e., in utero and under
maternal care, are thought to induce epigenetic modifica-
tions of gene expression in the brain that persist into
adulthood when they can ultimately contribute to mal-
adaptive stress-coping behaviors (329). On top of that,
epigenetic modifications of the stress response are not
limited to the environment during early life. As described
above, chronic social defeat stress, an animal model to
induce depressive-like behaviors in adult animals, acts in
part via persistent changes of the epigenome, and so do
other “stressors” in adulthood, which we will describe at
the end of this section.
1. Postnatal early life stress
In mammals, the quality of early life is primarily
determined by maternal care and accessibility to nutri-
tion. In mice and rats alike, maternal care takes the form
of arched-back nursing (AB) and licking/grooming (LG),
two behavioral traits exhibited by most rodent species but
which vary greatly between strains (45). These two ma-
ternal demeanors critically influence the offspring’s be-
havior and shape their responsiveness to stress and their
level of anxiety (229). At the molecular level, such respon-
siveness is in part regulated by glucocorticoid and gluco-
corticoid receptors (GR). High levels of circulating gluco-
corticoids raise the body’s alertness and increase the
stress response, while lower levels result in a more “re-
laxed” behavior and attenuate the stress response. Con-
versely, high levels of GR in forebrain areas such as the
hippocampus provide a negative feedback that reduces
the production of glucocorticoids and thereby dampens
the stress response (reviewed in Ref. 305). Intriguingly,
offspring of high-LG-ABN mothers show increased GR
expression and reduced reactivity to stress, whereas off-
spring of low-LG-ABN mothers have decreased GR ex-
pression and increased stress reactivity (199).
Both the reactivity to stress and the GR system are
subject to epigenetic modifications in early life (Fig. 5). In
the offspring of high LG-ABN female rats, the expression
of GR exon 17 is increased, which is accompanied by DNA
hypomethylation and H3K9 hyperacetylation in its pro-
moter region, which is bound by the transcription factor
NGFI-A (also known as Egr-1 or Zif268) (360). In contrast,
in the offspring of low LG-ABN females, the GR exon 17
promoter is unchanged in terms of histone acetylation,
yet hypermethylated at the DNA level, and less bound by
NGFI-A, which is accompanied by increased GR exon 17
expression. Remarkably, the binding of NGFI-A to the GR
promoter region is required for the occurrence of DNA
methylation changes, as site-directed mutagenesis against
the 3= binding site of NGFI-A within the GR promoter not
only abolished NGFI-A binding, but also promoter meth-
ylation (358). This finding suggests that the transcription
factor NGFI-A itself or its yet to be determined interaction
with members of the DNA methylation machinery convey
the methylation changes.
Importantly, although stable, these epigenetic changes
can be reversed by environmental or pharmacological
manipulations. Cross-fostering of pups, or treatment with
the HDACi TSA, leads to GR promoter DNA hypomethy-
lation and histone hyperacetylation in low LG-ABN off-
spring (360). Likewise, methyl supplementation via the
administration of L-methionine, a SAM precursor, can re-
verse the GR-mediated maternal programming of the
stress response (361). Both treatments have further been
shown to modulate the transcriptome in the hippocampus
in both high and low LG-ABN offspring (359), which
suggests that the type of maternal care not only influences
DNA methylation and histone acetylation at the GR pro-
moter, but also on other genes.
Crucially, the implication of epigenetic regulation of
GR was recently confirmed in a study involving post
mortem human brain samples (228). In this study, the
mRNA levels of hippocampal GR exon 1F, the human
homolog of the rat exon 17, were decreased and the DNA
methylation level in its promoter region correspondingly
increased in suicide victims with a history of childhood
abuse, but not in age-matched control subjects including
suicide victims without such history and people having
died from other causes. These findings strongly suggest
that in rodents and humans alike, childhood neglect can
cause life-long epigenetic alterations of gene expression
in the brain’s stress system (Fig. 5).
It should be noted, however, that a recent study
found a somewhat contradictory result in that DNA meth-
ylation might not be causally involved in reducing GR
expression (7). Thus human post mortem hippocampal
samples of persons with major depressive disorder did
not exhibit changes in the DNA methylation of the GR
promoter region, despite its mRNA levels being reduced.
Instead, NGFI-A levels were significantly reduced, sug-
gesting that the GR expression is rather caused by a
depression-related deficit in NGFI-A. However, as the
samples in these studies did not have a history of child-
hood abuse, it cannot be ruled out that the pathomecha-
nisms leading to stress differ depending on the etiological
circumstances.
Early life stress can further be experimentally in-
duced by exposing neonates to maternal separation or to
an aggressive foster mother. Investigating the epigenetic
and behavioral consequences of maternal separation in
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mice, a recent study found that periodic mother-infant
separations led to DNA hypomethylation in the promoter
region of the arginine vasopressin (avp) gene and a con-
comitant increase in the expression of avp in the hypo-
thalamus (245), a gene and brain region, respectively,
implicated in the brain circuitry activated by stress-cop-
ing. These molecular changes were installed as early as 6
wk of age, persisted into adulthood, and were accompa-
nied by increased helplessness towards stressful situa-
tions.
Another study investigated whether early life
abuse mimicked by a stressed and abusive foster
mother results in epigenetic programming of adult be-
havior. Early life maltreatment was found to induce
persistent DNA hypermethylation in the BDNFIV and
IX promoter regions in the rat prefrontal cortex that
lasted into adulthood and magnified with age (292).
DNA hypermethylation was further accompanied by
decreased total BDNF expression, and both could be
reversed by infusion of the DNMT1 inhibitor zebularine.
FIG. 5. The early life environment epigenetically shapes the stress response later in life in both rats and humans. A: in rats, low maternal care,
and in humans, parental abuse, lead to increased DNA methylation in the promoter region of the glucocorticoid receptor (GR) gene, which impinges
on its gene expression in the hippocampus, a brain area implicated in the stress response. Note that in rats, the expression of the GR gene has in
addition been shown to depend on the transcription factor NGF1-A, which cannot bind the GR promoter region when hypermethylated. These
epigenetic and gene expression changes persist into adulthood, when they lead to a heightened stress response, at least in the rat model. B: high
maternal care in rats, indicated by a high rate of licking and grooming and arch-back nursing, and the absence of parental abuse in humans, do not
increase the promoter methylation of the glucocorticoid receptor, which in turn allows for elevated gene expression that is, at least in rats, mediated
by NGF1-A. Again, both epigenetic and gene expression changes have been shown to persist into adulthood, when they result in a lowered stress
response, at least in the rat model. Note that in humans, the behavioral consequences of low versus high GR promoter methylation are not known.
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Although these animals were not tested behaviorally,
this study provides further evidence that the early life
environment can leave life-long marks on the epig-
enome. Noteworthy, such marks might get installed
with some delay, as the GR exon 17 promoter DNA
methylation was found to be unchanged until 7 days
after the last maternal separation in the rat hippocam-
pus (70).
Finally, a highly intriguing observation of early life
stress is that it might also affect subsequent generations.
For instance, rat pups raised by mothers that display high
nurturing levels become high nurturing mothers them-
selves (93), raising the possibility that the epigenetic pro-
gramming of the stress response can have behaviorally
transmitted transgenerational effects. Two recent studies
further extended this observation to the chromatin level
itself. In the first, female pups of abusive mothers gave
birth to offspring with DNA methylation profiles in the
prefrontal BDNF promoter strikingly similar to their own
(292). And in the second, maternal stress-induced DNA
methylation changes at the MeCP2, CB1 (cannabinoid
receptor 1) and CRFR2 (corticotropin-releasing factor 2)
genes were similar in the sperm of males subjected to
maternal stress, and fascinatingly, also in the brain of
their offspring, which themselves did not experience any
maternal stress, but showed comparable levels of anxiety
and depression-like phenotypes (95). If such behaviorally
induced transgenerational epigenetic inheritance will get
further confirmed, and its evidence extended from the
mere, albeit stunning correlative evidence to a more firm
proof, epigenetics would have the potential to revolution-
ize the perception of the inheritance of acquired traits.
2. Prenatal early life stress
The brain and with it the stress response are highly
susceptible to environmental contingencies during devel-
opment, which also includes the prenatal period (23, 210).
Although the consequences of an aversive prenatal envi-
ronment have been investigated for a long time, surpris-
ingly few studies have experimentally addressed the po-
tential of epigenetic mechanisms in mediating these long-
term consequences (71). In mice, chronic variable stress
to pregnant mothers led to increased depressive-like be-
haviors in their male offspring, which was accompanied
by increased amygdala transcription of the stress hor-
mone corticotropin-releasing factor (CRF) and decreased
hippocampal transcription of GR (244). These changes
were paralleled by decreased and increased promoter
DNA methylation, respectively, which suggests that pre-
natal stress activates the epigenetic machinery to modu-
late the stress response later in life. Interestingly, these
changes were only observed when prenatal stress oc-
curred during the first trimester, but not later, highlighting
this period as very susceptible to environmental influ-
ences. Also, the behavioral and molecular differences
were exclusively observed in male offspring, which is
indicative of sex differences in brain development during
that time and warrants further studies.
Stunningly, in humans, pregnant women with depres-
sion or anxiety-related disorders during their third trimes-
ter were found to have neonates (both sexes) with a
hypermethylated promoter region of GR exon 1F in leu-
kocytes, which correlated proportionally with the degree
of maternal depression (256). Intriguingly, 3 mo later,
infants with hypermethylated GR exon 1F at birth dis-
played higher saliva corticosterone levels. Follow-up
studies are still pending. From the present standpoint it is,
however, not clear how maternal stress, which is suppos-
edly “perceived” in the mother’s brain, could translate
onto the epigenetic niveau in the blood and brain of the
offspring. One contact point between the mother and the
fetus is the placenta, where early pregnancy stress did
indeed reduce DNMT1 levels (244). But, whether this is
also the case for late pregnancy stress, plus the exact
signaling pathways behind this observation, remain to be
determined.
3. Other postnatal “stressors”
Novelty, threats, and forms of physical discomfort all
represent stressful situations, and several examples
thereof have been demonstrated to activate the epigenetic
machinery in the adult brain.
A) NOVELTY. Remarkably, the exposure to a novel en-
vironment alone, be that an unfamiliar box or a water
tank, has been shown to be sufficient to induce H3 phos-
phoacetylation changes in the rat hippocampus (25, 60).
Although no memory tasks have been performed in these
studies, their findings highlight the necessity for proper
control groups when memory-related epigenetic mecha-
nisms are under investigation. The “stress-alone” group,
i.e., before the actual learning procedure starts, should
also to be taken into consideration.
B) THREATS. Similar to chronic social defeat stress
leading to depressive-like phenotypes, the mere reminder
of an aggressor or a predator, i.e., its odor, can lead to
symptoms reminiscent of posttraumatic stress disorder.
For example, the exposure to cat odor was recently
shown to not only lead to heightened anxiety, but also to
broad DNA methylation changes in the rat hippocampus,
including the promoter region of disc-large associated
protein 2 (Dlgap2) (53), a component of the postsynaptic
density.
C) RESTRAINT. Finally, physical restraint for 2 h/day led
to a transient decrease in BDNF mRNA (exons I, IV, and
IX) expression as soon as 2 h after the end of the immo-
bilization, which was accompanied by hypoacetylated H3
and H4 levels in their respective promoter regions in the
rat hippocampus (97). Twenty-four hours after immobili-
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zation, both the transcript and acetylation levels were
back to baseline.
Taken together, these findings underscore the rapid
dynamics of epigenetic changes in response to a variety of
environmental stimuli, and as a consequence, the need for
proper experimental design to rule out confounding vari-
ables in response to stress. This is particularly important
when learning and memory are under investigation, as
animals are often trained with novel objects or in novel
environments.
VI. PATHOLOGICAL EPIGENETIC REGULATION
III: NEURODEGENERATIVE DISORDERS
In contrast to the developmental disorders listed
above, which have an obvious epigenetic component, the
evidence for an epigenetic implication in adult-onset neu-
rodegenerative disorders is not as clear-cut. Nonetheless,
emerging evidence indicates that epigenetic mechanisms
are indeed involved in the pathogenesis of various neuro-
degenerative disorders (Table 5), be that causally or at
least in a modifying manner. This in turn is increasingly
often leading to the use of epigenetic drugs to treat these
disorders, with justified therapeutic potential. However,
as in the case of Alzheimer’s disease, multiple and diverg-
ing findings suggest multiple and complex mechanisms of
an epigenetic deregulation that once again illustrate the
need for a more thorough understanding of these aberrant
mechanisms.
A. Huntington’s Disease
Huntington’s disease (HD) is a rare, hereditary neu-
rodegenerative disorder with the hallmark symptom be-
ing a loss of coordinated movement, as well as additional
symptoms such as progressive cognitive decline and mus-
cle atrophy. Symptoms are generally first manifest be-
tween midlife (ages 35–50), but can appear from any age.
During HD progression, neurons are progressively lost.
The striatum is the brain region most prominently af-
fected, although multiple other regions including substan-
tia nigra, cortex, and cerebellum are also struck by HD.
On a cellular level, spiny neurons of the striatum appear
to be the most vulnerable cellular subtype.
TABLE 5. Epigenetic mechanisms in neurodegenerative disorders
Disorder Epigenetic Modification Mechanism Organism Brain Area Reference Nos.
Huntington’s
disease
Histone acetylation + Poly-Q extension of huntingtin binds
and inhibits HATs CBP and p300
Human cell culture and
Drosophila
Photoreceptor
neurons
322, 323
Histone methylation * H3K9 trimethylation is enhanced Mouse Cortex 320
Alzheimer’s disease Histone acetylation * AICD, the intracellular cleavage product
of APP recruits the HAT TIP60
Human cell culture NA 40
PS1 mutations prevent degradation of
CBP
Human cell culture and
mouse neuronal
culture
NA 216
p25/Cdk5 activation inhibits HDAC1 Mouse Hippocampus 159
Histone acetylation + APP overexpression leads to H3 and H4
hypoacetylation and decreased CBP
levels
Mouse neuronal culture NA 293
PS1 and PS2 mutations reduce CBP
expression
Mouse Cortex 299
H4 acetylation is reduced in APP/PS1
mice
Mouse Hippocampus 94
DNA methylation + Hypomethylation of PS1 enhances
-amyloid formation
Human cell culture NA 300
DNMT1 expression is decreased Macaque Cortex 366
DNA methylation *+ PS1 promoter is hypomethylated, yet
other genes hypermethylated
Human post mortem
brain
Cortex 354
Parkinson’s disease Histone acetylation + -Synuclein binds to the chromatin and
reduces histone acetylation
Human cell culture and
Drosophila
NA 169
Friedreich’s ataxia Histone acetylation +
/Histone
methylation *
FXN expansion is accompanied by H3
and H4 hypoacetylation and elevated
H3K9 trimethylation
Human cell culture NA 133
Amyotrophic lateral
sclerosis
Histone acetylation + SOD1 point mutations are paralleled by
histone hypoacetylation
Mouse Spinal cord 293
Histone acetylation HDAC2 protein expression is up-,
HDAC11 protein expression is
downregulated in ALS cases
Human post mortem Brain and
spinal cord
149
AICD, APP intracellular domain; ALS, amyotrophic lateral sclerosis; APP, amyloid precursor protein; CBP, CREB-binding protein; Cdk5,
cyclin-dependent kinase 5; DNMT1, DNA methyltransferase 1; FXN, frataxin; H, histone; HAT, histone acetyltransferase; HDAC, histone deacetylase;
K, lysine; NA, not applicable; PS, presenillin; Q, glutamine; SOD1, superoxide dismutase 1.
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HD is caused by an abnormally high number (over
36) of CAG repeats in the 5= end of the coding region of
the huntingtin gene. The number of repeats affects the
severity and age of onset of disease. Thus, while a critical
component of HD is inheritance of a HD allele with large
number of repeats, this number can be increased or re-
duced between generations. High numbers of repeats re-
sult in a mutant Huntingtin protein containing a 5= poly-
glutamine repeat region, which has altered characteristics
such as a gain of self-aggregation properties (29).
A number of differing theories exist as to the precise
mechanism for progressive neuronal death observed in
HD. Both loss-of-function and toxic gain-of-function the-
ories have been proposed, but recent studies using trans-
genic mouse models overexpressing high-CAG-repeat
huntingtin, which recapitulates many of the features of
HD, strongly support a gain-of-function. One of the theo-
ries for mutant huntingtin toxicity is based on the finding
that the polyglutamine repeat region binds to the acetyl-
transferase domain of two histone acetyltransferases,
CBP and p300/CBP-associated factor (322, 323). This ap-
pears to sequester these actyltransferases, resulting in
globally reduced H3 and H4 acetylation levels, and altered
gene expression. Further supporting the notion of HD as
a disease of aberrantly reduced histone acetylation, treat-
ment with various HDAC inhibitors has been shown to
rescue histone acetylation levels and to improve neuro-
degeneration and pathological symptoms in cellular, Dro-
sophila, and mouse models (88, 104, 135, 296, 322, 337)
(Table 6).
Despite the wealth of evidence that histone acetyla-
tion is deregulated but amenable to pharmacological
treatments in HD, it is important to note that beneficial
effects of HDACis might also be mediated by cytoplasmic
proteins, rather than histone proteins. Thus, upon treat-
ment of mouse striatal cultured cells with HD pathology
with the HDAC6-specific inhibitor tubacin, -tubulin acet-
ylation was increased and some of HD pathology were
reversed (77). Likewise, genetic and pharmacological
HDAC6 inhibition proved also beneficial against oxidative
stress-induced neuronal damage, and this effect was
seemingly transcription-independent (288). It is thus en-
tirely possible that more non-histone proteins are affected
by the use of HDACis, and further studies are required to
determine the precise contribution of both histone and
non-histone protein hypoacetylation in HD (for a review,
see Ref. 39).
In addition to acetylation, histone methylation is also
altered in mouse models of HD, in which H3K9, a mark for
transcriptional repression (172), was found to be hyper-
methylated (89, 320). Interestingly, these epigenetic
marks and HD-typical locomotor deficits could be re-
stored by intraperitoneal injection of DNA/RNA-binding
anthracyclines, potent anticancer drugs (320), as well as
by the HDACi phenylbutyrate (104). These findings point
to a joint deregulation of both histone acetylation and
methylation in HD, but the precise molecular mechanism
linking these epigenetic marks remains to be investigated.
B. Alzheimer’s Disease
Alzheimer’s disease (AD) is the most common of all
neurodegenerative disorders, with current worldwide es-
timates of 20 million affected people. AD is clinically
characterized by a progressive decline in cognitive abili-
ties, and histologically by amyloid plaques, neurofibrillary
tangles, and neuronal loss. Neurons are progressively lost
during disease progression from the hippocampus, cor-
tex, and other regions. Almost all AD cases are sporadic,
but various rare hereditary forms of AD have been iden-
tified, all of which involve mutations in amyloid precursor
protein (APP), or in presenilins 1 and 2 (PS1 and -2),
which are involved in the processing of APP to form the
-amyloid constituents of amyloid plaques.
A number of differing epigenetic abnormalities per-
taining to histone acetylation have been reported in AD.
During the processing of APP, an intracellular fragment is
released into the cytosol, which was shown in vitro to
interact with the HAT TIP60 through the protein Fe65,
and the resulting complex was suggested to enhance gene
transcription (40). This complex may also play a role in
histone H4 acetylation required for DNA repair, an inter-
esting notion considering that the amount of DNA double-
strand breaks are increased in AD and AD models (4, 159).
Furthermore, PS1 was shown to play an inhibitory role on
the HAT CBP through proteasomal degradation, and mu-
tations in PS1 found in hereditary AD were shown to
result in aberrantly high CBP activity (216). Also, p25/
Cdk5, a kinase complex implicated in AD and other neu-
rodegenerative disorders, was shown to inhibit HDAC1,
rendering neurons susceptible to DNA damage, cell cycle
reentry, and ultimately cell death (159). These findings
suggest that AD could be a disease of aberrantly increased
histone acetylation. In support of this notion, it was
shown that overexpression of HDAC1 could rescue
against p25/Cdk5-mediated DNA damage and neurotoxic-
ity. Along similar lines, overexpression of the class III
HDAC SIRT1 rescued neurons not only against p25/Cdk5-
mediated neurotoxicity (160), but also against another
transgenic mouse model of AD (APP/PS1) (78) via mech-
anisms involving p53 and -secretase, respectively, al-
though it is not clear whether in these cases SIRT1 had a
deacetylating effect on histones as well.
On the other hand, paradoxically, a substantial body
of evidence rather supports the notion that inhibition of
HDACs can be protective and beneficial in AD. Thus APP
overexpression in cultured cortical neurons led to H3 and
H4 hypoacetylation, and was paralleled by decreased CBP
levels (293). Similarly, loss-of-function mutations in genes
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coding for PS1 and PS2 not only impaired synaptic plas-
ticity, and spatial and contextual memory, but also re-
duced the expression of CBP and CBP/CREB target genes
such as c-fos and BDNF (299). Moreover, in the p25/Cdk5
model of neurodegeneration, treatment with the broad
HDACi SB not only increased H3 and H4 acetylation
levels, but also resulted in the reestablishment of learning
abilities, as well as access to long-term memories that had
been ablated by prior hyperactivation of p25/Cdk5 (92).
Similarly, both general and class I-selective HDAC inhib-
itors have been shown to ameliorate cognitive defects in
transgenic AD mouse harboring hereditary AD mutation
(158, 287). Together, this second line of data collectively
suggests that AD is characterized by an overall hypoacety-
lation, which might be amenable to rescue with the use of
HDACis. One recent preliminary study indeed supports
this notion, in that H4 acetylation was decreased, yet
reversible by TSA treatment in the hippocampus of the
APP/PS1 mouse model of AD (94).
How can these two differing lines of evidence be
reconciled? One possibility is that the onset of neurode-
generation pathologically differs from later stages of the
disease. Under this scenario, p25/Cdk5 hyperactivity
might at first result in HDAC1 inhibition, which triggers
aberrant gene expression programs such as that of cell
cycle genes. Since such a program is, however, against the
destiny of neuronal cells, these supposedly react by coun-
teracting this hyperactivation and by permanently shut-
ting down any further gene expression increases, likely
via epigenetic mechanisms including histone hypoacety-
lation. This, in turn, would then explain why at later
disease stages, HDACis have been shown to be efficient
against several AD and AD-related pathologies. However,
this remains speculation at this point.
Alternatively, histone hyper- and hypoacetylation are
not contradictory, and it might as well be that they co-
occur depending on brain area, cell type, or even in the
same cell at different loci. Thus the epigenetic mecha-
nisms at play in AD are most likely more complex than
anticipated. Furthermore, as the HDAC inhibitors re-
ported to ameliorate AD symptoms are either general or
only partially selective, more specific (e.g., genetic)
means are required to identify the HDAC(s) that are re-
sponsible for the therapeutic effects, and thus may also be
involved in AD pathology. For example, it was recently
found that HDAC2, but not HDAC1, is a negative regulator
of memory formation and synaptic plasticity, and that
HDAC2 is responsible for the beneficial effects of HDAC
inhibitors on learning and memory in wild-type mice
(121). It is therefore tempting to speculate that HDAC2
may mediate the effects observed in the AD models, yet
other HDACs might also be at work.
In addition to histone acetylation, changes to DNA
methylation have also been implicated in AD pathogene-
sis. Thus hypomethylation of the PS1 promoter region
was found to enhance PS1 expression and -amyloid
formation in a culture model (99, 300). Additionally, in a
primate model of AD, DNMT1 was decreased in the cor-
tex and associated with increased APP mRNA expression
(366). Moreoever, the PS1 promoter was found to be
hypomethylated in late-onset AD brains compared with
controls (354), providing further evidence for DNA hy-
pomethylation to be critically involved in AD. However, as
other AD-related genes were hypermethylated (354), a
more thorough examination of specific loci and identifi-
cation of the specific mechanisms are still required to
better understand the importance of DNA methylation in
AD pathology.
C. Parkinson’s Disease
Parkinson’s disease (PD) is the second most common
late-onset neurodegenerative disorder, affecting between
0.5 and 1 million individuals in the United States as of
2000 (152). This disease is characterized by progressive
loss of muscle rigidity and tremor, and slowing of physical
movement. The primary affected region is the substantia
nigra, in which loss of dopaminergic neurons results in
decreased formation and action of dopamine. While the
majority of PD cases are sporadic in nature, a number of
mutations have been identified as causing hereditary PD,
including -synuclein, a component of large intracellular
eosinophilic aggregations found in PD called Lewy bodies,
PARK2, ubiquitin COOH-terminal hydrolase L1 (UCHL1), com-
ponents of the ubiquitin/proteasome machinery, and
PTEN induced putative kinase 1 (PINK1), a kinase in-
volved in mitochondrial stress response. Because of these
genes, defects in the ubiquitination/proteasome machin-
ery resulting in loss of protein clearance, and mitochon-
drial dysfunctions have been hypothesized to be patho-
logical mechanisms in PD (239).
Over the recent years, epigenetic components to PD
pathology have also been detected. For example, nuclear
-synuclein was found to directly bind to histones and to
reduce levels of histone acetylation in a Drosophila model
of PD, suggesting that histone hypoacetylation may be
causally involved in PD pathology (169). Supporting this
notion, inhibition of SIRT2 has been shown to rescue
neurotoxicity in Drosophila (260), although it is not
known whether this affected also the histone level. How-
ever, treatment of dopaminergic cell lines with the HDACi
TSA exacerbated PD-related neurotoxic damage, caution-
ing against the general use of HDACis in PD (355).
D. Other Neurodegenerative Diseases
1. Friedreich’s ataxia
Friedreich’s ataxia (FA) is a neurodegenerative dis-
ease characterized by severe coordination problems as
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well as vision and hearing impairments. FA has a preva-
lence of 1:50,000 in the United States and is thought to be
caused primarily by a GAA triplet expansion in the gene
coding for frataxin (FXN), which leads to silencing of the
mitochondrial protein product of this gene (262). This
gene silencing was accompanied by H3 and H4 hypoacety-
lation and by increased H3K9 trimethylation (133), sug-
gesting the implication of epigenetic mechanisms in FA.
Interestingly, HDACis TSA and SAHA proved effective in
reversing these acetylation deficits in FA patient-derived
cell culture (133), and a novel HDACi, HDACi 106 had the
same effect in a mouse model of FA (278). HDACis have
therefore been proposed as therapeutic potential against
FA-related pathologies.
2. Amyotrophic lateral sclerosis
Some evidence also points to the therapeutic poten-
tial of HDACis against amyotrophic lateral sclerosis (ALS)
symptoms. ALS is a neurodegenerative disease mainly
affecting motor neurons with symptoms broadly encom-
passing loss of control of voluntary muscle movements
and muscular atrophy. The prevalence of ALS in the
United States is 1 in 300,000. Although most cases of
ALS occur sporadically,10% are inherited, and these are
thought to be caused by mutations in the gene superoxide
dismutase 1 (SOD1). In a SOD1 point mutation mouse
model of ALS, ALS symptoms were molecularly accom-
panied by reduced CBP levels in motorneurons (293), but
VPA and TSA administration restored the resulting his-
tone acetylation deficits together with the motor deficits
back to baseline (294). However, it should be noted that
VPA failed to reduce the premature mortality of these
mice. A recent human post mortem study provided fur-
ther evidence for a deregulation of histone acetylation
in ALS. Comparing the protein expression levels of all
class I, II, and IV HDACs in the ALS brain and spinal
cord, HDAC2 and HDAC11 were up- and downregu-
lated, respectively (149). The functional consequences
in terms of histone acetylation changes and resulting
gene expression changes remain, however, unclear.
From the examples presented above, a general pic-
ture emerges that the core pathological pathways for a
given neurodevelopmental, neuropsychological, or neuro-
degenerative disorder often interact or interfere with
components of the epigenetic machinery (Fig. 6). How-
ever, this is a relatively recent notion, and our knowledge
of epigenetic mechanisms at play in these disorders is still
in the stages of infancy. As illustrated by the body of
research in AD, there are likely multiple bidirectional
changes to the epigenetic machinery, and resulting com-
plex changes to the chromatin landscape. Hence, these
epigenetic changes will have to be painstakingly exam-
ined for various types of modifications at a global scale to
gain a clearer idea of the changes that occur during the
progression of a given disorder. In turn, such an approach
may identify unanticipated epigenetic changes, even in
brain disorders for which pathological epigenetic mecha-
nisms have not yet been identified.
VII. PATHOLOGICAL EPIGENETIC REGULATION
IV: OTHER BRAIN DISORDERS
A. Glioma
While cancers of the brain are relatively rare, they are
among the most aggressive and lethal types. This is well
exemplified by Glioblastoma Multiforme (GBM), the most
common form of brain tumor which, at the relatively rare
occurrence of 2–8 cases per 100,000 in the United States,
still accounts for over half of all primary brain parenchy-
mal tumors (257, 303). The median survival time after
diagnosis is less than 12 mo, and current treatment op-
tions are largely limited to palliative and symptomatic
measures. With the exception of glioblastoma observed in
some cancer-prone hereditary disorders such as Li-Frau-
meni Syndrome, Turcot Syndrome, or neurofibromatosis,
GBMs originate in a sporadic manner (303). Amplifica-
tions of oncogenes such as epidermal growth factor re-
ceptor (EGFR), or tumor suppressors such as phospha-
tase and tensin homolog (PTEN), are often observed and
are considered to contribute to progression of the dis-
ease. The specific cell of origin for GBMs has not been
conclusively determined, but is thought to be of glial, glial
progenitor, or neural progenitor identity (202).
Aberrant changes to DNA methylation are a fre-
quently occurring and important feature of GBM that has
been noted since the 1980s (101). At a gross level, it is a
loss of DNA methylation that is most often observed.
While the implications of this epigenetic alteration are
poorly understood, it has been shown that global hypom-
ethylation triggers genomic instability and is sufficient to
lead to tumorigenesis (106).
On the other hand, controversially, subsequent ge-
nome-scale examination of DNA methylation has revealed
that many loci, in particular promoter CpG islands, are
hypermethylated in GBM, leading to transcriptional sup-
pression. One of the best-characterized genes silenced in
this manner is O6-methyl guanine methyltransferase
(MGMT). MGMT is a DNA repair protein, which removes
methyl and chloroethyl groups from O6 of guanine, thus
repairing a potentially apoptosis-triggering DNA lesion.
MGMT expression/activity positively correlates with re-
sistance against various alkylating chemotherapeutics
such as temozolomide. Conversely, methylation of MGMT,
which is expected to result in reduced expression, has
been found to be an important determinant of whether
tumor cells are responsive to temozolomide: tumors
which displayed MGMT methylation were found to be
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more responsive to temozolomide chemotherapy than
those which did not (132). Thus tumor biopsy evaluation
of MGMT methylation may become a routine diagnostic
tool to determine therapeutic approaches for individual
patients.
Importantly, numerous important tumor suppressors
such as PTEN, P16INK4A, or p53 have also been shown to
be hypermethylated and reduced in expression in subsets
of GBM (13, 65, 111), indicating that epigenetic suppres-
sion of various tumor suppressors may constitute strate-
gies by which cancer cells gain a selective advantage
during tumor formation/progression. While there is signif-
icant variation among individual cases in the tumor sup-
pressor genes that are hypermethylated and/or sup-
pressed, in particular, P16INK4A was estimated to be
reduced in expression in over 70% of GBMs, and in these
cases, over 70% exhibited hypermethylation of the pro-
moter region. Thus it appears that CpG island hypermeth-
ylation is highly relevant in GBM, both as a disease-
driving mechanism and as an important modifier for che-
motherapy efficacy. However, the mechanisms that drive
this hypermethylation are still poorly understood, but one
possibility is the overexpression and/or hyperactivation
of DNMTs (201).
FIG. 6. Overview of the best-documented examples of epigenetic deregulation in neurodevelopmental and neurodegenerative disorders. For
example, Rubinstein-Taybi Syndrome is characterized by an overall histone hyperacetylation under pathological conditions, whereas a hallmark of
Rett Syndrome is an overall decrease in DNA methylation associated with increased histone acetylation. For some of the diseases, the epigenetic
deregulation could be attributed to particular loci. For instance, under physiological conditions, the FMR1 and -2 genes are transcriptionally active,
whereas in the neurodevelopmental disease Fragile-X Syndrome, they are silenced due to DNA hypermethylation. Conversely, the gene huntingtin
(Htt) is silenced under physiological conditions, whereas in the neurodegenerative disease Huntington’s Disease it becomes hyperacetylated and,
as a consequence, transcriptionally active. Another example is the gene FXN, which under healthy conditions is acetylated, but in the neurode-
generative disease Friedreich’s Ataxia undergoes deacetylation plus gene-silencing histone methylation. Finally, the gene PS1 is under physiological
conditions strongly methylated, but in Alzheimer’s Disease there is evidence that this is no longer the case, which results in increased PS1 gene
transcription. Epigenetic modifications that silence gene expression are depicted in blue; epigenetic modifications that favor gene expression are
in red. For details and gene names, see text.
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In addition to aberrant changes in DNA methylation,
there are a few reports of changes in HDAC expression,
and even mutations in HDACs and HMTs in GBM (207,
266). Thus it is possible that histone modifications may
also play a role in GBM pathogenesis. Furthermore, as
with many other cancer types, HDAC inhibitors have been
tested in cellular and animal models for GBMs as well as
other brain tumors, and have been shown to negatively
affect cell growth and survival, and increase the sensitiv-
ity to radiation and chemotherapy (248).
It is important to note that cancers of the brain
such as GBMs are diseases of a highly different nature
compared with neurodegenerative disorders, involving
hyperproliferation of non-neuronal populations. An-
other important distinction is that the goal of brain
cancer therapy is the targeted toxicity and/or growth
suppression of selected subpopulations (cancer cells),
as opposed to the goal of protection against toxicity in
neurodegenerative disorders. However, some impor-
tant parallels can be made in that GBMs also appear to
involve complex deregulation of epigenetic mecha-
nisms, as exemplified by the involvement of both hy-
pomethylation and hypermethylation of DNA in GBM
pathogenesis. As in AD and other neurodegenerative
disorders, it is clear that a more detailed understanding
of the epigenetic changes that occur, as well as the
development of more selective drugs that target the
epigenetic machinery, are still required. Finally, under-
standing the role of epigenetics in the two different
types of diseases may go hand in hand. For example,
when designing a therapeutic strategy against one, epi-
genetic mechanisms that may trigger or contribute to
the other should not be targeted. Conversely, tools and
drugs developed for the therapy of neurodegenerative
disorders may prove to be useful in therapy of brain
cancers as well.
B. Stroke/Ischemia
Stroke and ischemia are the cause of death for an
average of more than 137,000 persons in the United States
every year (134, 232). Cellularly, ischemic damage results
in an increased transcription rate of genes that control
cellular stress, inflammatory, and apoptotic response
genes. Interestingly, several groups have reported that
treatment with various HDACis, SAHA, SB, and TSA, both
prior to and following stroke induction, confers neuro-
protection (82, 115, 142, 161, 162, 277, 282, 316). The
idea that HDACis might be neuroprotective against
ischemic cell damage originates in the observation that
following cerebral artery occlusion, an animal model to
induce ischemia, H3 acetylation levels show a pro-
nounced decrease (82).
The neuroprotective effects of HDACis resulted in a
decrease in infarct volume (82, 162, 282), behavioral im-
provements relative to animals not given inhibitors (162,
282), decrease in expression of several factors associated
with apoptosis (142, 162, 277), and cellular stress and
inflammation (82, 162, 282), in addition to stimulation of
neurogenesis following ischemic damage (161). Molecu-
larly, administration of HDACis led to an overall increase
in H3 and H4 acetylation, potentially mediated by HDAC4
(82), which was accompanied by increased gene expres-
sion of the transcription factors CREB and BDNF (161),
as well as several molecular chaperones such as heat-
shock protein HSP70 (82, 162, 282). However, so far,
gene-specific promoter analyses addressing the effect on
histone acetylation both before and after HDACi treat-
ment are to date still lacking. Nonetheless, these studies
point to a potential use of HDACis against stroke and
merit to be evaluated more thoroughly in the future.
C. The Aging Brain
The aged brain differs drastically from its adult coun-
terpart in terms of gene expression programs (204), which
are thought to contribute to age-associated memory im-
pairments (269). Recently, two studies have shown that
age-related epigenetic differences might account for cog-
nitive decline during aging. The first assessed histone
acetylation changes that are induced by learning in both
aged (16 mo old) and adult (3 mo old) mice (268). Stun-
ningly, of several histone PTMs examined, only H4K12
acetylation was absent after learning in the aged animals,
specifically of the promoter region of learning and mem-
ory-related genes. SAHA treatment in the aged group not
only restored their learning deficits, but also H4K12 levels
comparable to nonaged animals, promoting this HDACi
treatment as a potent memory enhancer. The second
study examined the DNA methylation of Arc (activity
regulated cytoskeletal-associated protein), a gene impor-
tant for memory consolidation and synaptic plasticity. Arc
transcripts were downregulated in aged rats (24–32 mo
old) compared with adult animals (9–12 mo old), which
was accompanied by increased DNA methylation in the
promoter region of the gene in the hippocampus (270).
Two studies with the same conclusion: the aged brain
seems to be characterized by accumulating epigenetic
silencing modifications, which shut down the expression
of genes that are important for learning and memory. The
aged brain is seemingly less plastic because of increased
chromatin condensation.
VIII. SYNOPSIS AND OUTLOOK
From the collective body of literature on epigenetic
mechanisms under both physiological and pathological
conditions in the brain, two summarizing statements can
be made. First, it is becoming increasingly evident that
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epigenetic mechanisms play an important modulatory
role in many (if not all) biological processes throughout
the brain. Second, these mechanisms are highly complex
(Fig. 6). When first mentioned, the concept of the “histone
code” stipulated that the reaction of a given cell to a given
environment can be characterized by a given set of his-
tone modifications (150, 344). Over the past year it has
become obvious that such a code is indeed applicable, but
must be extended to a more general concept of an “epi-
genetic code” that also includes DNA methylation (113,
343), and hence bears an intensive and extraordinarily
complex cross-talk among these different levels of epige-
netic modifications (43, 181).
In the brain, one of the most heterogeneous tissues
overall, the complexity of epigenetic modifications is even
further potentiated. First, different brain areas react dif-
ferently to the same environmental challenge. For in-
stance, whereas chronic treatment with the antidepres-
sant imipramine decreased HDAC5 levels in the hip-
pocampus, the same treatment increased HDAC5 levels in
the NAc (285, 340). Second, within the same brain area,
different cell types are not only by default characterized
by a specific epigenomic profile (see Ref. 54 for a recent
approach to characterize neuronal and non-neuronal cell
types in terms of trimethylation of H3K4 in the human
prefrontal cortex), but they also react differently to iden-
tical environmental stimuli. This is illustrated by the case
of GABAergic and dopaminergic neurons that in the brain
of schizophrenic patients seem to be characterized by
DNA hyper- and hypomethylation, respectively (1, 123,
145). Third, another level of complexity that has so far
received little attention is the observation that sex differ-
ences in the brain are in part caused by epigenetic differ-
ences, and that consequently, environmental factors such
as maternal nutrition can have sex-dependent effects
(225). Finally, our understanding of the brain’s epigenetic
machinery is far from being complete. For instance, using
a large-scale proteomic approach on nuclear proteins in
the brain, several hitherto unidentified histone PTMs
could be detected (345), the function of which remains
enigmatic. Likewise, a recent study unveiled an entirely
new type of epigenetic modification in the CNS, 5-hy-
droxymethylcytosine (173), with still mostly unclear func-
tion.
But even outside the brain, we are far from a com-
plete picture of precisely how the epigenetic machinery
works. Although HATs and HDACs are commonly re-
garded as transcription-activating and -repressing epige-
netic enzymes, respectively, both have recently been
found to bind to actively transcribed genes (356), suggest-
ing that their impact on gene transcription is more subtle
than anticipated. Moreover, enzymes of the epigenetic
machinery themselves can be posttranslationally regu-
lated (e.g., Ref. 254), the significance of and the extent to
which this occurs remain poorly understood. Another
observation is that although epigenetic enzymes such as
HDACs supposedly act primarily in the nucleus, some
HDACs such as class IIb HDACs are predominantly cyto-
plasmic (156). The functions of HDACs outside the nu-
cleus have only recently started to be explored. Similar
open questions concern the mechanisms that govern the
shuttling of HDACs to and from the nucleus (e.g., Ref.
334) and the regulating pathways upstream of the epige-
netic machinery (291).
A. Clinical Considerations
Despite this complexity of epigenetic mechanisms
and the multitude of open questions, several epigenetic
drugs have received considerable attention and have
spurred justified hope as therapeutic approaches against
both neurodevelopmental and neurodegenerative dis-
eases. This is particularly true for HDAC inhibitors (2, 90,
128, 156) because histone acetylation is not only down-
regulated in AD, HD, and RTT, but also reversible by
HDACis, which was accompanied by other alleviating
effects for these disorders (Table 6). As a consequence,
several HDACis are currently in preclinical or phase I/II
trials for the treatment of HD and AD.
Surprisingly, however, most of the currently used
HDACis still act unspecifically and target several classes
of HDACs, if not non-histone targets as well (156). More-
over, as they are often administered systemically, i.e.,
intraperitoneally in animals models and orally in human
subjects, such treatments face the risk of undesired side-
effects, not only in the target tissue, but also body-widely.
Plus, whether a treatment regimen with general HDAC
inhibitors in humans is feasible for prolonged periods is
another unresolved question. Likewise, little is known
about the downstream effect of one epigenetic drug on
other epigenetic marks, as the epigenetic machinery is
characterized by the above-mentioned extensive cross-
talks (43, 181). Indeed, HDACis themselves can be neuro-
toxic (163, 297), further cautioning against their unsur-
veyed use.
More specific epigenetic treatments are thus highly
warranted (129). Ideally, compounds for the treatment of
epigenetic brain disorders would be characterized by an
efficient penetration of the blood-brain barrier, by a suf-
ficient metabolic stability in the target tissue, and by a
high, as of now not achieved, degree of selectivity (156).
B. Future Directions
To develop more potent and more selective epige-
netic treatments against brain disorders, a better under-
standing of the epigenetic machinery is thus required. To
achieve this, two main research approaches should be
pursued. First, genetic models of various epigenetic com-
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ponents are invaluable tools to increase our understand-
ing of epigenetic mechanisms at play in physiological
brain functions. In particular, conditional loss-of-function
mutants are invaluable in deciphering why a certain epi-
genetic mechanism is important during a particular stage
of development or for a particular phenotype, but not in
other circumstances. In combination with cell-type spe-
cific promoters, this constitutes a promising avenue to
study epigenetic mechanisms in a time- and location-
restricted manner.
Second, epigenomic approaches at different time
points and in different cell types should be highly infor-
mative to disentangle the complexity of the epigenetic
regulatory network and to identify the individual loci
affected in each disease. This can be addressed with
chromatin immunoprecipitation techniques coupled with
deep sequencing technology (ChIP-Seq). In analogy to
stem cell research, where cells are already being epig-
enomically analyzed at different stages of their differen-
tiation (e.g., Ref. 76), different developmental stages of
the nervous system and of its cell types in response to
specific environments will have to be studied this way, as
each of them is predicted to have its unique epigenetic
code. In conjunction with whole-genome gene expression
profiles, the future of epigenetic research in the brain will
hopefully give a clearer picture of how the brain reacts to
TABLE 6. Investigated epigenetic “treatments” against neurodevelopmental, neuropsychiatric, and
neurodegenerative disorders
Disease Disease Model
Epigenetic “Therapy” and Route of
Administration Beneficial Effect Reference Nos.
Neurodevelopmental
Rubinstein-Taybi CBP-deficient mouse models HDACis SAHA, TSA, icv and ip Rescue of long-term memory
deficits
6, 170
Fragile X Patient-derived cell lines 5-aza, HDACis phenylbutyrate,
SB, TSA, within medium
Rescue of FMR gene
silencing
55, 56, 330, 331
Schizophrenia Reeler mice HDACi VPA, sc Reversal of reelin
hypomethylation
338
Neuropsychiatric
Cocaine addiction Mice HDACi SB, ip Facilitated extinction of
cocaine-induced behaviors
215
Alcohol addiction Rats HDACi TSA, ip Reduced withdrawal
behaviors
261
Depression Mouse model of chronic
social defeat stress
HDACi SB, ip Reduced depressive-like
behaviors
340
HDACi MS-275, st into NAc by
osmotic pumps
Reduced depressive-like
behaviors
66
Mouse tail suspension HDACi SB, ip Reduced depressive-like
behaviors
302
Neurodegenerative
Huntington’s
disease
Htt-transfected human cell
lines
HDACis SB, TSA, SAHA,
within medium
Rescue of histone
hypoacetylation
322
Htt-like mouse cultured cells HDACi tubacin, within medium Reversal of neurotoxicity 77
R6/2 mice HDACis phenylbutyrate and
SB, ip
Reversal of neurotoxicity 88, 296
HDACi SAHA and 4b, orally Reversal of neurotoxicity
and behavioral deficits
135, 337
82Q mice HDACi phenylbutyrate, ip Reversal of neurotoxicity 104
Alzheimer’s disease p25/Cdk5 mice HDACi SB, ip Reestablishment of memory
capacities and spine
number
92
Tg2576 mice HDACi phenylbutyrate, ip Reestablishment of memory
capacities and reduced
phosphorylated tau levels
287
APPswe/PS1dE9 mice HDACis VPA, SB, and
SAHA, ip
Reestablishment of memory
capacities
158
APP/PS1 mice HDACi TSA, ip Reestablishment of memory
capacities and LTP
impairments
94
Friedreich’s ataxia Frataxin knock-in mice HDACi 106, sc Reversal of acetylation
changes
278
Amyotrophic lateral
sclerosis
SOD1 point mutation mice HDACi VPA and TSA, ip Reversal of motor deficits 294
APP, amyloid precursor protein; CBP, CREB-binding protein; Cdk5, cyclin-dependent kinase 5; FMR, fragile X mental retardation; HDACi, HDAC
inhibitor; Htt, huntingtin; icv, intracerebroventricular; ip, intraperitoneal; NAc, nucleus accumbens; PS1, presenilin 1; sc, subcutaneous; st,
stereotaxical; SAHA, suberoylanilide acid; SOD1, superoxide dismutase 1; SB, sodium butyrate; TSA, trichostatin A; VPA, valproic acid; 5-aza,
5-aza-2-deoxycytidine.
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a given environment by tissue- and cell-type specific epi-
genetic codes on a certain set of genes.
Lastly, it is tempting to speculate that epigenetic
mechanisms, which by definition touch upon the most
stable carrier of information over time, i.e., the chromatin,
have the inherent potential to explain changes in behavior
that are long-lasting. Indeed, findings that DNA methyl-
ation marks were still present in the brain several months
after an episode of early life stress (360) or 1 mo after a
learning event (236) point towards that direction. How-
ever, such stability of DNA methylation marks does not
apply for histone modifications, which are of more tran-
sient nature and have, for instance in yeast, an overall
half-life on the order of only minutes (155). It is likely that
such short half-lives also characterize histone modifica-
tions in the brain. So, then, how could histone modifica-
tions explain long-lasting behavioral changes? One possi-
bility is the extensive cross-talk between histone and DNA
modifications, by which the former might serve as a mere
trigger for the latter (which in many studies might simply
not have been investigated), and that DNA methylation is
the actual carrier of stable changes (see also Ref. 73 for a
recent discussion of this scenario). Another option is that
some histone modifications, hardly detectable by the cur-
rent technology, do indeed persist, and thus leave a mark
on the chromatin that can later be recognized and poten-
tiated by context-specific coregulators and transcription
factors. The future will certainly see more detailed mech-
anistic studies at higher resolution that address these
fascinating questions.
In sum, epigenetic mechanisms in the nervous sys-
tem, or “neuroepigenetics,” constitute an exciting new
field of research with the premise to not only better
understand how plastic adaptive responses to the envi-
ronment lead to stable gene expression and behavioral
changes, but also to provide new therapeutic approaches
for a broad variety of brain disorders. Yet more work is
still required until we get there.
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